US20080193437A1 - Immunostimulatory oligonucleotide multimers - Google Patents
Immunostimulatory oligonucleotide multimers Download PDFInfo
- Publication number
- US20080193437A1 US20080193437A1 US11/876,913 US87691307A US2008193437A1 US 20080193437 A1 US20080193437 A1 US 20080193437A1 US 87691307 A US87691307 A US 87691307A US 2008193437 A1 US2008193437 A1 US 2008193437A1
- Authority
- US
- United States
- Prior art keywords
- aac
- ttc
- caa
- ctt
- ctgtct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 120
- 230000003308 immunostimulating effect Effects 0.000 title claims abstract description 73
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 claims description 23
- 208000006673 asthma Diseases 0.000 claims description 23
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 150000004713 phosphodiesters Chemical class 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 244000052769 pathogen Species 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 230000001717 pathogenic effect Effects 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 9
- 239000013566 allergen Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 208000026935 allergic disease Diseases 0.000 claims description 8
- 230000007815 allergy Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000443 aerosol Substances 0.000 claims description 7
- 208000037883 airway inflammation Diseases 0.000 claims description 7
- 239000007933 dermal patch Substances 0.000 claims description 7
- 239000003889 eye drop Substances 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 239000002324 mouth wash Substances 0.000 claims description 7
- 229940051866 mouthwash Drugs 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 abstract description 27
- 102000039446 nucleic acids Human genes 0.000 abstract description 27
- 150000007523 nucleic acids Chemical class 0.000 abstract description 26
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 59
- 230000004048 modification Effects 0.000 description 59
- 238000012986 modification Methods 0.000 description 59
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 34
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 34
- 125000001369 canonical nucleoside group Chemical group 0.000 description 29
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 28
- 150000001875 compounds Chemical class 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- 108010047761 Interferon-alpha Proteins 0.000 description 25
- 102000006992 Interferon-alpha Human genes 0.000 description 25
- 241000282414 Homo sapiens Species 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 21
- 229910052739 hydrogen Inorganic materials 0.000 description 21
- 239000001257 hydrogen Substances 0.000 description 21
- 125000005647 linker group Chemical group 0.000 description 19
- 239000002777 nucleoside Substances 0.000 description 17
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 15
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 150000003833 nucleoside derivatives Chemical class 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 13
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 12
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 239000002718 pyrimidine nucleoside Substances 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 9
- 229940037003 alum Drugs 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000002342 ribonucleoside Substances 0.000 description 9
- 102000002689 Toll-like receptor Human genes 0.000 description 8
- 108020000411 Toll-like receptor Proteins 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 7
- CKZJTNZSBMVFSU-UBKIQSJTSA-N 4-amino-5-hydroxy-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical class C1=C(O)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKZJTNZSBMVFSU-UBKIQSJTSA-N 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 7
- -1 CpG nucleic acid Chemical class 0.000 description 6
- 102000004388 Interleukin-4 Human genes 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- 239000000370 acceptor Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002794 lymphocyte assay Methods 0.000 description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 201000009961 allergic asthma Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 150000003834 purine nucleoside derivatives Chemical class 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- PHNDUXLWAVSUAL-SHYZEUOFSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-sulfanylidenepyrimidin-2-one Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 PHNDUXLWAVSUAL-SHYZEUOFSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 4
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 4
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 4
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 4
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 4
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 4
- 206010003557 Asthma exercise induced Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 4
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 4
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 4
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 208000028004 allergic respiratory disease Diseases 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 150000008209 arabinosides Chemical class 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 4
- 235000020932 food allergy Nutrition 0.000 description 4
- 229940029575 guanosine Drugs 0.000 description 4
- 150000002402 hexoses Chemical class 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002212 purine nucleoside Substances 0.000 description 4
- 201000004335 respiratory allergy Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108091081548 Palindromic sequence Proteins 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 0 [2H]C1=*C(=C)C(C)C=C1C Chemical compound [2H]C1=*C(=C)C(C)C=C1C 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 3
- 229960004784 allergens Drugs 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 239000002215 arabinonucleoside Substances 0.000 description 3
- 150000001479 arabinose derivatives Chemical class 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 201000010659 intrinsic asthma Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229910052757 nitrogen Chemical group 0.000 description 3
- 208000007892 occupational asthma Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 150000002972 pentoses Chemical group 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229950010550 resiquimod Drugs 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 241000726445 Viroids Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000809 air pollutant Substances 0.000 description 2
- 231100001243 air pollutant Toxicity 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003221 ear drop Substances 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000003517 fume Substances 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000018711 interleukin-13 production Effects 0.000 description 2
- 230000017307 interleukin-4 production Effects 0.000 description 2
- 230000022023 interleukin-5 production Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000020030 perry Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical class NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- TVICROIWXBFQEL-UHFFFAOYSA-N 6-(ethylamino)-1h-pyrimidin-2-one Chemical compound CCNC1=CC=NC(=O)N1 TVICROIWXBFQEL-UHFFFAOYSA-N 0.000 description 1
- NLLCDONDZDHLCI-UHFFFAOYSA-N 6-amino-5-hydroxy-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1O NLLCDONDZDHLCI-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- QJXHTVNUKBBDIV-UHFFFAOYSA-N CC.CC.CC Chemical compound CC.CC.CC QJXHTVNUKBBDIV-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 description 1
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical compound O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 101150071746 Pbsn gene Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241001201572 Sarcocystis masoni Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102100027009 Toll-like receptor 10 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000034662 activation of innate immune response Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000012916 chromogenic reagent Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010021083 hen egg lysozyme Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000024696 nocturnal asthma Diseases 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000008229 sterile water for irrigation Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
Definitions
- the invention relates to immune stimulation by oligonucleotide analogs.
- CpG DNAs induce innate immune cells to produce Th1 cytokines that promote cytotoxic T lymphocyte (CTL) responses and production of immunoglobulins by B cells.
- CTL cytotoxic T lymphocyte
- the immunostimulatory properties of CpG DNAs have allowed their use as therapeutic agents for a broad spectrum of disease indications including cancers, viral and bacterial infections, inflammatory disorders and as adjuvant in immunotherapy.
- Kandimalla et al, Biochem. Biophys. Res. Commun. 306 (2003) 948-953 teaches that the presence of a secondary structure in CpG DNAs significantly affected their activity depending on the position and nature of the secondary structure, that the presence of a hairpin structure at the 5′-end abrogated stimulatory activity, and that the same structure at the 3′-end had an insignificant effect on stimulatory activity but caused lower IL-6 secretion and contributed to higher stability against nucleases.
- the invention provides an immunostimulatory oligonucleotide the sequence of which is at least partially self-complementary.
- the immunostimulatory nucleic acid comprises an oligonucleotide sequence containing at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-dideoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy
- the immunostimulatory nucleic acid is from about 2 to about 50 nucleotides in length. In certain embodiments the immunostimulatory nucleic acid is from about 12 to about 26 nucleotides in length. In some embodiments, the oligonucleotides each have from about 3 to about 35 nucleoside residues, in further embodiments from about 4 to about 30 nucleoside residues, in even further embodiments from about 4 to about 20 nucleoside residues. In some embodiments, the oligonucleotides have from about 5 to about 18, or from about 5 to about 14, nucleoside residues. As used herein, the term “about” implies that the exact number is not critical.
- the number of nucleoside residues in the oligonucleotides is not critical, and oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above. In some embodiments, one or more of the oligonucleotides have 11 nucleotides.
- the invention provides an immunomer comprising at least two oligonucleotides linked by a non-nucleotide linker, wherein the sequences of the immunostimulatory oligonucleotides are at least partially self-complementary.
- At least one of the oligonucleotides contains at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-dideoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy-5-hydroxycytidine, 2′-deoxy-N4-alkyl-cytidine, 2′-deoxy-4
- the immunostimulatory nucleic acid is from about 2 to about 50 nucleotides in length. In certain embodiments the immunostimulatory nucleic acid is from about 12 to about 26 nucleotides in length. In some embodiments, the oligonucleotides each have from about 3 to about 35 nucleoside residues, or from about 4 to about 30 nucleoside residues, or from about 4 to about 20 nucleoside residues. In some embodiments, the oligonucleotides have from about 5 to about 18, or from about 5 to about 14, nucleoside residues. As used herein, the term “about” implies that the exact number is not critical.
- the number of nucleoside residues in the oligonucleotides is not critical, and oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above. In some embodiments, one or more of the oligonucleotides have 11 nucleotides.
- compositions comprise any one of the compositions disclosed in the first and second aspects of the invention either alone or in combination and a pharmaceutically acceptable carrier.
- the invention provides a method for generating an immune response in a vertebrate.
- This method comprises administering to the vertebrate any one of the compositions, alone or in combination, disclosed in the first, second and third aspects of the invention.
- the compositions disclosed herein can be administered through any suitable route of administration including, but not limited to, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash.
- the invention provides a method for therapeutically treating a vertebrate having cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen.
- This method comprises administering to the vertebrate any one of the compositions, alone or in combination, disclosed in the first, second and third aspects of the invention.
- the compositions disclosed herein can be administered through any suitable route of administration including, but not limited to, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop, ear drop and mouthwash.
- the invention provides a method for preventing cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen in a vertebrate.
- This method comprises administering to the vertebrate any one of the compositions, alone or in combination, disclosed in the first, second and third aspects of the invention.
- the compositions disclosed herein can be administered through any suitable route of administration including, but not limited to, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop, ear drop and mouthwash.
- FIGS. 1A and 1B are representations of various embodiments of the invention.
- m and n are independently 0-1000 (SEQ ID NO 41).
- FIG. 2 is a synthetic scheme for the parallel synthesis of immunomers of the invention.
- FIG. 3 depicts a group of representative small molecule linkers suitable for linear synthesis of immunomers of the invention.
- FIG. 4 is a synthetic scheme for the linear synthesis of immunomers of the invention.
- FIG. 5 depicts a group of representative small molecule linkers suitable for parallel synthesis of immunomers of the invention.
- the invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents for immunotherapy applications.
- the invention also provides methods for generating, enhancing and modifying the immune response caused by immunostimulatory compounds used for immunotherapy applications such as, but not limited to, treatment and/or prevention of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies, and bacteria, parasitic, and viral infections in adult and pediatric human and veterinary applications.
- Allergic asthma is a certain embodied condition for treatment by the present methods and compounds.
- the invention further provides compounds having optimal levels of immunostimulatory effect for immunotherapy and methods for making and using such compounds.
- immunostimulatory oligonucleotides/immunomers of the invention are useful as adjuvants in combination with DNA vaccines, antibodies, allergens, chemotherapeutic agents, and antisense oligonucleotides.
- the invention provides an immunostimulatory oligonucleotide the sequence of which is at least partially self-complementary.
- the immunostimulatory nucleic acid comprises an nucleic acid sequence containing at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-dideoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy-5-hydroxyc
- the immunostimulatory oligonucleotide is from about 2 to about 50 nucleotides in length. In certain embodiments the immunostimulatory oligonucleotide is from about 12 to about 26 nucleotides in length. In some embodiments, the oligonucleotides are from about 3 to about 35 nucleoside residues, or from about 4 to about 30 nucleoside residues, or from about 4 to about 20 nucleoside residues. In some embodiments, the oligonucleotides have from about 5 to about 18, or from about 5 to about 14, nucleoside residues. As used herein, the term “about” implies that the exact number is not critical.
- the number of nucleoside residues in the oligonucleotides is not critical, and oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above. In some embodiments, one or more of the oligonucleotides have 11 nucleotides.
- the complementary sequence of the oligonucleotides allows for intermolecular hydrogen bonding thereby giving the oligonucleotides secondary structure. Additional oligonucleotides can bind together thereby creating a chain, or multimers, of oligonucleotides according to the invention.
- the invention provides an immunomer comprising at least two oligonucleotides linked by a non-nucleotide linker, wherein the sequences of the immunostimulatory oligonucleotides are at least partially self-complementary.
- At least one of the oligonucleotides contains at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-dideoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy-5-hydroxycytidine, 2′-deoxy-N4-alkyl-cytidine, 2′-deoxy-4
- immunostimulatory nucleic acid comprises a structure as detailed in formula (I).
- Domains may be from about 2 to about 12 nucleotides in length.
- Domain A may be 5′-3′ or 3′-5′ or 2′-5′ DNA, RNA, RNA-DNA, DNA-RNA having a palindromic or self-complementary domain containing or not containing at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-deoxy-5-halocytosine, 2′-deoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substitute
- Domain A will have more than one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*.
- Domain B is a linker joining Domains A and C that may be a 3′-′5′ linkage, a 2′-5′ linkage, a 3′-3′ linkage, a phosphate group, a nucleoside, or a non-nucleoside linker that may be aliphatic, aromatic, aryl, cyclic, chiral, achiral, a peptide, a carbohydrate, a lipid, a fatty acid, mono- tri- or hexapolyethylene glycol, or a heterocyclic moiety.
- Domain C may be 5′-3′ or 3′-5′,2′-5′ DNA, RNA, RNA-DNA, DNA-RNA Poly I-Poly C having a palindromic or self-complementary sequence, containing or not containing a dinucleotide selected from the group consisting of CpG, C*pG, C*pG*, CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-deoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy
- the immunostimulatory dinucleotide is not CpG.
- Domain B is preferably a non-nucleotidic linker connecting oligonucleotides of Domain A and Domain C, which are referred to as “immunomers.”
- Domain C does not have the dinucleotide CpG, C*pG, C*pG* or CpG*.
- the oligonucleotides contained in formula (I) are from about 2 to about 50 nucleotides in length. In certain embodiments the oligonucleotides contained in formula (I) are from about 12 to about 26 nucleotides in length. In some embodiments, the oligonucleotides each have from about 3 to about 35 nucleoside residues, preferably from about 4 to about 30 nucleoside residues, more preferably from about 4 to about 20 nucleoside residues. In some embodiments, the oligonucleotides have from about 5 to about 18, or from about 5 to about 14, nucleoside residues. As used herein, the term “about” implies that the exact number is not critical.
- the number of nucleoside residues in the oligonucleotides is not critical, and oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above. In some embodiments, one or more of the oligonucleotides have 11 nucleotides.
- a self-complementary sequence as used herein refers to a base sequence which, upon suitable alignment, may form intramolecular or, more typically, intermolecular basepairing between G-C, A-T, A-U and/or G-U wobble pairs.
- the extent of self-complementarity is at least 50 percent.
- an 8-mer that is at least 50 percent self-complementary may have a sequence capable of forming 4, 5, 6, 7, or 8 G-C, A-T, A-U and/or G-U wobble basepairs.
- Such basepairs may but need not necessarily involve bases located at either end of the self-complementary immunostimulatory oligonucleotide and/or immunomer.
- nucleic acid stabilization may be important to the immunostimulatory oligonucleotide and/or immunomer
- the degree of self-complementarity may depend on the alignment between immunostimulatory oligonucleotide and/or immunomer, and such alignment may or may not include single- or multiple-nucleoside overhangs. In other embodiments, the degree of self-complementarity is at least 60 percent, at least 70 percent, at least 80 percent, at least 90 percent, or even 100 percent.
- the plurality of immunostimulatory oligonucleotides and/or immunomers may, but need not, include sequences which are at least partially complementary to one another.
- the plurality of immunostimulatory oligonucleotides and/or immunomers includes an immunostimulatory oligonucleotide and/or immunomer having a first sequence and an immunostimulatory oligonucleotide and/or immunomer having a second sequence, wherein the first sequence and the second sequence are at least 50 percent complementary.
- first sequence and the second sequence are at least 50 percent complementary.
- two 8-mers that are at least 50 percent complementary they may form 4, 5, 6, 7, or 8 G-C, A-T, A-U, and/or G-U wobble basepairs.
- Such basepairs may but need not necessarily involve bases located at either end of the complementary immunostimulatory oligonucleotides and/or immunomers.
- the degree of complementarity may depend on the alignment between immunostimulatory oligonucleotides and/or immunomers, and such alignment may or may not include single- or multiple-nucleoside overhangs. In other embodiments, the degree of complementarity is at least 60 percent, at least 70 percent, at least 80 percent, at least 90 percent, or even 100 percent.
- the immunostimulatory nucleic acid will have a structure as detailed in formula (II).
- the depicted immunostimulatory nucleic acid/immunomer compounds have secondary structure because the sequences of the domains are complementary allowing for intermolecular hydrogen bonding.
- Domains A and A′ may or may not be identical, domains A and C may or may not be identical, domains A and C′ may or may not be identical, domains A′ and C may or may not be identical, domains A′ and C′ may or may not be identical, domains B and B′ may or may not be identical and domains C and C′ may or may not be identical.
- additional immunomers can bind through intermolecular hydrogen bonding thereby creating a chain, or multimers, of immunomers according to the invention.
- n can be any number of continuous, self complementary immunomer compounds.
- complementary means having the ability to hybridize to a nucleic acid. Such hybridization is ordinarily the result of hydrogen bonding between complementary strands, preferably to form Watson-Crick or Hoogsteen base pairs, although other modes of hydrogen bonding, as well as base stacking can also lead to hybridization.
- secondary structure refers to intermolecular hydrogen bonding. Intermolecular hydrogen bonding results in the formation of a duplexed nucleic acid molecule.
- “Palindromic sequence” shall mean an inverted repeat (i.e., a sequence such as ABCDEE′D′C′B′A′ in which A and A′, B and B′, etc., are bases capable of forming the usual Watson-Crick base pairs. In vivo, such sequences may form double-stranded structures.
- the CpG nucleic acid contains a palindromic sequence.
- a palindromic sequence used in this context refers to a palindrome in which the CpG is part of the palindrome. In some embodiments the CpG is the center of the palindrome. In another embodiment the CpG nucleic acid is free of a palindrome.
- An immunostimulatory nucleic acid that is free of a palindrome is one in which the CpG dinucleotide is not part of a palindrome.
- Such an oligonucleotide may include a palindrome in which the CpG is not the center of the palindrome.
- oligonucleotide refers to a polynucleoside formed from a plurality of linked nucleoside units. Such oligonucleotides can be obtained from existing nucleic acid sources, including genomic or cDNA, but are preferably produced by synthetic methods.
- each nucleoside unit includes a heterocyclic base and a pentofuranosyl, 2′-deoxypentfuranosyl, trehalose, arabinose, 2′-deoxy-2′-substituted arabinose, 2′-O-substituted arabinose or hexose sugar group.
- the nucleoside residues can be coupled to each other by any of the numerous known internucleoside linkages.
- Such internucleoside linkages include, without limitation, phosphodiester, phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboalkoxy, acetamidate, carbamate, morpholino, borano, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone internucleoside linkages.
- oligonucleotide also encompasses polynucleosides having one or more stereospecific internucleoside linkage (e.g., (RP)- or (SP)-phosphorothioate, alkylphosphonate, or phosphotriester linkages).
- RP RP
- SP stereospecific internucleoside linkage
- oligonucleotide and dinucleotide are expressly intended to include polynucleosides and dinucleosides having any such internucleoside linkage, whether or not the linkage comprises a phosphate group.
- these internucleoside linkages may be phosphodiester, phosphorothioate, or phosphorodithioate linkages, or combinations thereof.
- oligonucleotide also encompasses polynucleosides having additional substituents including, without limitation, protein groups, lipophilic groups, intercalating agents, diamines, folic acid, cholesterol and adamantane.
- oligonucleotide also encompasses any other nucleobase containing polymer, including, without limitation, peptide nucleic acids (PNA), peptide nucleic acids with phosphate groups (PHONA), locked nucleic acids (LNA), morpholino-backbone oligonucleotides, and oligonucleotides having backbone sections with alkyl linkers or amino linkers.
- PNA peptide nucleic acids
- PONA peptide nucleic acids with phosphate groups
- LNA locked nucleic acids
- morpholino-backbone oligonucleotides oligonucleotides having backbone sections with alkyl linkers or amino linkers.
- the oligonucleotides of the invention can include naturally occurring nucleosides, modified nucleosides, or mixtures thereof.
- modified nucleoside is a nucleoside that includes a modified heterocyclic base, a modified sugar moiety, or a combination thereof.
- the modified nucleoside is a non-natural pyrimidine or purine nucleoside, as herein described.
- the modified nucleoside is a 2′-substituted ribonucleoside an arabinonucleoside or a 2′-deoxy-2′-substituted-arabinoside.
- 2′-substituted ribonucleoside or “2′-substituted arabinoside” includes ribonucleosides or arabinonucleosides in which the hydroxyl group at the 2′ position of the pentose moiety is substituted to produce a 2′-substituted or 2′-O-substituted ribonucleoside.
- such substitution is with a lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an aryl group having 6-10 carbon atoms, wherein such alkyl, or aryl group may be unsubstituted or may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carboalkoxy, or amino groups.
- 2′-O-substituted ribonucleosides or 2′-O-substituted-arabinosides include, without limitation 2′-O-methylribonucleosides or 2′-O-methylarabinosides and 2′-O-methoxyethoxyribonucleosides or 2′-O-methoxyethoxyarabinosides.
- 2′-substituted ribonucleoside or “2′-substituted arabinoside” also includes ribonucleosides or arabinonucleosides in which the 2′-hydroxyl group is replaced with a lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an amino or halo group.
- Examples of such 2′-substituted ribonucleosides or 2′-substituted arabinosides include, without limitation, 2′-amino, 2′-fluoro, 2′-allyl, and 2′-propargyl ribonucleosides or arabinosides.
- oligonucleotide includes hybrid and chimeric oligonucleotides.
- a “chimeric oligonucleotide” is an oligonucleotide having more than one type of internucleoside linkage.
- One non-limiting example of such a chimeric oligonucleotide is a chimeric oligonucleotide comprising a phosphorothioate, phosphodiester or phosphorodithioate region and non-ionic linkages such as alkylphosphonate or alkylphosphonothioate linkages (see e.g., Pederson et al. U.S. Pat. Nos. 5,635,377 and 5,366,878).
- hybrid oligonucleotide is an oligonucleotide having more than one type of nucleoside.
- One non-limiting example of such a hybrid oligonucleotide comprises a ribonucleotide or 2′ substituted ribonucleotide region, and a deoxyribonucleotide region (see, e.g., Metelev and Agrawal, U.S. Pat. Nos. 5,652,355, 6,346,614 and 6,143,881).
- nucleic acid molecule of the invention can be two immunomers linked by way of a non-nucleotidic linker.
- At least one immunostimulatory oligonucleotide of the invention comprises an immunostimulatory dinucleotide of the formula 5′-Pyr-Pur-3′, wherein Pyr is a natural pyrimidine nucleoside or analog thereof and Pur is a natural purine nucleoside or analog thereof.
- pyrimidine nucleoside refers to a nucleoside wherein the base component of the nucleoside is a pyrimidine base.
- purine nucleoside refers to a nucleoside wherein the base component of the nucleoside is a purine base.
- a “synthetic” pyrimidine or purine nucleoside includes a non-naturally occurring pyrimidine or purine base, a non-naturally occurring sugar moiety, or a combination thereof.
- pyrimidine nucleosides in the immunostimulatory oligonucleotides and/or immunomers used in the method according to the invention have the structure (III):
- D is a hydrogen bond donor
- D′ is selected from the group consisting of hydrogen, hydrogen bond donor, hydrogen bond acceptor, hydrophilic group, hydrophobic group, electron withdrawing group and electron donating group;
- A is a hydrogen bond acceptor or a hydrophilic group
- A′ is selected from the group consisting of hydrogen bond acceptor, hydrophilic group, hydrophobic group, electron withdrawing group and electron donating group;
- X is carbon or nitrogen
- S′ is a pentose or hexose sugar ring, or a non-naturally occurring sugar.
- the sugar ring is derivatized with a phosphate moiety, modified phosphate moiety, or other linker moiety suitable for linking the pyrimidine nucleoside to another nucleoside or nucleoside analog.
- hydrogen bond donors include, without limitation, —NH—, —NH 2 , —SH and —OH.
- Preferred hydrogen bond acceptors include, without limitation, C ⁇ O, C ⁇ S, and the ring nitrogen atoms of an aromatic heterocycle, e.g., N3 of cytosine.
- the base moiety in (III) is a non-naturally occurring pyrimidine base.
- preferred non-naturally occurring pyrimidine bases include, without limitation, 5-hydroxycytosine, 5-hydroxymethylcytosine, N4-alkylcytosine, or N4-ethylcytosine, and 4-thiouracil.
- the sugar moiety S′ in (III) is a non-naturally occurring sugar moiety.
- a “naturally occurring sugar moiety” is a sugar moiety that occurs naturally as part of nucleic acid, e.g., ribose and 2′-deoxyribose and a “non-naturally occurring sugar moiety” is any sugar that does not occur naturally as part of a nucleic acid, but which can be used in the backbone for an oligonucleotide, e.g, hexose.
- Arabinose and arabinose derivatives are non-limiting examples of sugar moieties.
- purine nucleoside analogs in immunostimulatory oligonucleotides and/or immunomers used in the method according to the invention have the structure (IV):
- D is a hydrogen bond donor
- D′ is selected from the group consisting of hydrogen, hydrogen bond donor, and hydrophilic group
- A is a hydrogen bond acceptor or a hydrophilic group
- X is carbon or nitrogen
- each L is independently selected from the group consisting of C, O, N and S;
- S′ is a pentose or hexose sugar ring, or a non-naturally occurring sugar.
- the sugar ring is derivatized with a phosphate moiety, modified phosphate moiety, or other linker moiety suitable for linking the pyrimidine nucleoside to another nucleoside or nucleoside analog.
- hydrogen bond donors include, without limitation, —NH—, —NH 2 , —SH and —OH.
- Preferred hydrogen bond acceptors include, without limitation, C ⁇ O, C ⁇ S, —NO 2 and the ring nitrogen atoms of an aromatic heterocycle, e.g., N1 of guanine.
- the base moiety in (IV) is a non-naturally occurring purine base.
- examples of preferred non-naturally occurring purine bases include, without limitation, 6-thioguanine and 7-deazaguanine.
- the sugar moiety S′ in (IV) is a naturally occurring sugar moiety, as described above for structure (III).
- compositions comprise any one of the compositions disclosed in the first and second of the invention either alone or in combination and a physiologically acceptable carrier.
- the term “physiologically acceptable” refers to a material that does not interfere with the effectiveness of the compositions of the first, second or third aspects of the invention and is compatible with a biological system such as a cell, cell culture, tissue, or organism.
- a biological system such as a cell, cell culture, tissue, or organism.
- the biological system is a living organism, such as a vertebrate.
- carrier encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, or other material well known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient, or diluent will depend on the route of administration for a particular application. The preparation of pharmaceutically acceptable formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990, ISBN: 0-912734-04-3.
- compositions of the invention may also include a cancer vaccine, including a cancer vaccine selected from EFG, Anti-idiotypic cancer vaccines, Gp75 antigen, GMK melanoma vaccine, MGV ganglioside conjugate vaccine, Her2/new, Ovarex®, M-Vax, O-Vax, L-Vax, STn-KHL Theratope®, BLP25 (MUC-1), liposomal idiotypic vaccine, Melacine®, peptide antigen vaccines, toxin/antigen vaccines, MVA-vased vaccine, PACIS, BCG vaccine, TA-HPV, TA-CIN, DISC-virus and ImmunCyst/TheraCys®.
- a cancer vaccine selected from EFG, Anti-idiotypic cancer vaccines, Gp75 antigen, GMK melanoma vaccine, MGV ganglioside conjugate vaccine, Her2/new, Ovarex®, M-Vax, O-Vax, L-Va
- the compositions of the first, second or third aspects of the invention may be covalently linked to an antigen or otherwise operatively associated with an antigen.
- the term “operatively associated with” refers to any association that maintains the activity of both the compositions of the first, second or third aspects of the invention and the antigen. Non-limiting examples of such operative associations include being part of the same liposome or other such delivery vehicle or reagent.
- such covalent linkage is at any position on the compositions of the first, second or third aspects of the invention other than an accessible 5′ end of an immunostimulatory oligonucleotide.
- the antigen may be attached at an internucleoside linkage or may be attached to the non-nucleotidic linker. Alternatively, the antigen may itself be the non-nucleotidic linker.
- compositions of the first, second or third aspects of the invention may include an oligonucleotide with antisense activity.
- antisense activity means that the oligonucleotide, when introduced into a cell or an animal, causes a reduction in the expression of the gene to which it is complementary.
- compositions of the first, second or third aspects of the invention may include an oligonucleotide sequence that is an aptamer.
- Aptamers are nucleic acid molecules that have been selected from random pools based on their ability to bind other molecules. Aptamers have been selected which bind nucleic acids, proteins, small organic compounds, and even entire organisms. These novel molecules have many potential uses in medicine and technology (see, e.g., Burgstaller P., et al. Curr Opin Drug Discov Devel. 5: 690-700 (2002)).
- compositions of the invention may be administered by any suitable route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form.
- the pharmaceutical compositions can be delivered using known procedures at dosages and for periods of time effective obtain the desired effect, e.g. the treatment of cancer, the treatment of infection and the treatment of autoimmune diseases.
- the pharmaceutical compositions are administered at a sufficient dosage to attain a blood level of the compositions of the first, second and/or third aspects of the invention from about 0.0001 micromolar to about 10 micromolar.
- a total dosage of immunostimulatory oligonucleotide and/or immunomer ranges from about 0.0001 mg per patient per day to about 200 mg per kg body weight per day. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
- Immunostimulatory oligonucleotides were created as immunomers using the following protocols for synthesis.
- the immunostimulatory oligonucleotides and/or immunomers of the invention may conveniently be synthesized using an automated synthesizer and phosphoramidite approach as schematically depicted in FIGS. 2 and 4 .
- the immunostimulatory oligonucleotides and/or immunomers are synthesized by a linear synthesis approach (see FIG. 2 ). Representative linkers for this synthesis are presented in FIG. 3 .
- linear synthesis refers to a synthesis that starts at one end of the immunomer and progresses linearly to the other end. Linear synthesis permits incorporation of either identical or un-identical (in terms of length, base composition and/or chemical modifications incorporated) monomeric units into the immunostimulatory oligonucleotides and/or immunomers.
- An alternative mode of synthesis for immunostimulatory oligonucleotides and/or immunomers is “parallel synthesis”, in which synthesis proceeds outward from a central linker moiety (see FIG. 4 ).
- Representative linkers for this method of synthesis are presented in FIG. 5 .
- a solid support attached linker can be used for parallel synthesis, as is described in U.S. Pat. No. 5,912,332.
- a universal solid support such as phosphate attached to controlled pore glass support, can be used.
- Parallel synthesis of immunostimulatory oligonucleotides and/or immunomers has several advantages over linear synthesis: (1) parallel synthesis permits the incorporation of identical monomeric units; (2) unlike in linear synthesis, both (or all) the monomeric units are synthesized at the same time, thereby the number of synthetic steps and the time required for the synthesis is the same as that of a monomeric unit; and (3) the reduction in synthetic steps improves purity and yield of the final immunomer product.
- the immunostimulatory oligonucleotides or immunomers according to the invention may conveniently be deprotected with concentrated ammonia solution or as recommended by the phosphoramidite supplier, if a modified nucleoside is incorporated.
- the product immunostimulatory oligonucleotides and/or immunomer is preferably purified by reversed phase HPLC, detritylated, desalted and dialyzed.
- compositions disclosed in the first second and third aspects of the invention can comprise the immunostimulatory oligonucleotide or immunomer alone or as oligonucleotide/immunomer conjugates.
- An oligonucleotide/immunomer conjugate comprises an oligonucleotide or immunomer, as described above, and an antigen conjugated to the oligonucleotide and/or immunomer at a position other than the accessible 5′ end.
- the non-nucleotidic linker comprises an antigen, which is conjugated to the oligonucleotide.
- the antigen is conjugated to the oligonucleotide at a position other than its 3′ end.
- the antigen produces a vaccine effect.
- the immunostimulatory oligonucleotide or immunomer alone or as oligonucleotide/immunomer conjugates can be administered in the methods discussed below.
- the antigen is optionally selected from antigens associated with a pathogen, antigens associated with a cancer, antigens associated with an auto-immune disorder, and antigens associated with other diseases such as, but not limited to, veterinary or pediatric diseases, or wherein the antigen is an allergen.
- the term “associated with” means that the antigen is present when the pathogen, cancer, auto-immune disorder, food allergy, skin allergy, respiratory allergy, asthma or other disease is present, but either is not present, or is present in reduced amounts, when the pathogen, cancer, auto-immune disorder, food allergy, skin allergy, respiratory allergy, or disease is absent.
- the immunomer is covalently linked to the antigen, or it is otherwise operatively associated with the antigen.
- the term “operatively associated with” refers to any association that maintains the activity of both immunomer and antigen. Nonlimiting examples of such operative associations include being part of the same liposome or other such delivery vehicle or reagent.
- such covalent linkage preferably is at any position on the immunomer other than an accessible 5′ end of an immunostimulatory oligonucleotide.
- the antigen may be attached at an internucleoside linkage or may be attached to the non-nucleotidic linker. Alternatively, the antigen may itself be the non-nucleotidic linker.
- the invention provides methods for generating and/or modulating an immune response in a vertebrate, such methods comprising administering to the vertebrate an immunomer or immunomer conjugate according to the invention.
- the vertebrate is a mammal.
- the term “mammal” is expressly intended to include humans.
- the immunomer or immunomer conjugate is administered to a vertebrate in need of immunostimulation.
- modulating means to increase or decrease the immunostimulatory activity of an immunostimulatory nucleic acid relative to that of the parent immunostimulatory nucleic acid.
- administration of immunomers can be by any suitable route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, intramuscular, intraperitonal, subcutaneous, intradermal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form.
- Administration of the therapeutic compositions of immunomers can be carried out using known procedures at dosages and for periods of time effective to reduce symptoms or surrogate markers of the disease.
- the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of immunomer from about 0.0001 micromolar to about 10 micromolar.
- a total dosage of immunomer ranges from about 0.001 mg per patient per day to about 200 mg per kg body weight per day. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
- Either the immunomer or the vaccine, or both, may optionally be linked to an immunogenic protein, such as keyhole limpet hemocyanin (KLH), cholera toxin B subunit, or any other immunogenic carrier protein or nonimmunogenic carrier protein.
- an immunogenic protein such as keyhole limpet hemocyanin (KLH), cholera toxin B subunit, or any other immunogenic carrier protein or nonimmunogenic carrier protein.
- KLH keyhole limpet hemocyanin
- MPL monophosphoryl lipid A
- alum and saponins, including QS-21, imiquimod, R848, or combinations thereof.
- TLRs Toll-like receptors
- PAMPs pathogen-associated molecular patterns
- TLRs Upon recognizing conserved pathogen-associated molecular products, TLRs activate host defense responses through their intracellular signaling domain, the Toll/interleukin-1 receptor (TIR) domain, and the downstream adaptor protein MyD88.
- TLR Toll-like receptor
- cytokines for example, interleukin-1 ⁇ ; IL-6 and tumor necrosis factor, TNF
- NK natural killer cells and T cells are also involved in the pro-inflammatory circuit.
- TLR ligands include, but are not limited to, lipoproteins; peptidoglycan, zymosan (TLR2), double-stranded RNA, polyI:polyC (TLR3), lipopolysaccharide, heat shock proteins, taxol Taxol® (TLR4), flagellin (TLR5), and imidazoquinolines-R848, resiquimod, imiquimod; ssRNA (TLR7/8), beta-lymphocytes (TLR10) and uropathogenic E. coli (TLR11).
- the methods according to this aspect of the invention are useful for model studies of the immune system.
- the methods are also useful for the prophylactic or therapeutic treatment of human or animal disease.
- the methods are useful for pediatric and veterinary vaccine applications.
- the invention provides methods for therapeutically treating a vertebrate having a disease or disorder, such methods comprising administering to the vertebrate an immunomer or immunomer conjugate according to the invention.
- the disease or disorder to be treated is cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, allergy, asthma or a disease caused by a pathogen.
- Pathogens include bacteria, parasites, fungi, viruses, viroids and prions.
- Administration is carried out as described for the fourth aspect of the invention.
- allergy includes, without limitation, food allergies atopic dermatitis, allergic rhinitis (also known as hay fever), allergic conjunctivitis, urticaria (also known as hives), respiratory allergies and allergic reactions to other substances such as latex, medications and insect stings or problems commonly resulting from allergic rhinitis-sinusitis, otitis media and COPD.
- airway inflammation includes, without limitation, asthma. Specific examples of asthma include, but are not limited to, allergic asthma, non-allergic asthma, exercised-induced asthma, occupational asthma, and nocturnal asthma.
- Allergic asthma is characterized by airway obstruction associated with allergies and triggered by substances called allergens. Triggers of allergic asthma include, but are not limited to, airborne pollens, molds, animal dander, house dust mites and cockroach droppings. Non-allergic asthma is caused by viral infections, certain medications or irritants found in the air, which aggravate the nose and airways.
- Triggers of non-allergic asthma include, but are not limited to, airborne particles (e.g., coal, chalk dust), air pollutants (e.g., tobacco smoke, wood smoke), strong odors or sprays (e.g., perfumes, household cleaners, cooking fumes, paints or varnishes), viral infections (e.g., colds, viral pneumonia, sinusitis, nasal polyps), aspirin-sensitivity, and gastroesophageal reflux disease (GERD).
- Exercise-induced asthma is triggered by vigorous physical activity. Symptoms of EIA occur to varying degrees in a majority of asthma sufferers and are likely to be triggered as a result of breathing cold, dry air while exercising.
- Triggers of EIA include, but are not limited to, breathing airborne pollens during exercise, breathing air pollutants during exercise, exercising with viral respiratory tract infections and exercising in cold, dry air.
- Occupational asthma is directly related to inhaling irritants and other potentially harmful substances found in the workplace.
- Triggers of occupational asthma include, but are not limited to, fumes, chemicals, gases, resins, metals, dusts, vapors and insecticides.
- autoimmune disorder refers to disorders in which “self” proteins undergo attack by the immune system. Such term includes autoimmune asthma.
- the immune response to CpG DNA includes activation of innate immune cells, proliferation of B cells, induction of Th1 cytokine secretion, and production of immunoglobulins (Ig).
- the activation of immune cells by CpG DNA occurs via Toll-like receptor 9 (TLR9), a molecular pattern recognition receptor.
- TLR9 Toll-like receptor 9
- CpG DNA induce strong Th1-dominant immune responses characterized by secretion of IL-12 and IFN- ⁇ tilde over ( ⁇ ) ⁇ .
- Immunomers (IMO) alone or as allergen conjugates decrease production of IL-4, IL-5, and IgE and reduce eosinophilia in mouse models of allergic asthma.
- IMO compounds also effectively reverse established atopic eosinophilic airway disease by converting a Th2 response to a Th1 response.
- OVA with alum is commonly used to establish a Th2-dominant immune response in various mouse and rat models.
- the Th2 immune response includes increased IL-4, IL-5, and IL-13 production, elevated serum levels of total and antigen-specific IgE, IgG1, and lower levels of IgG2a.
- IMO compounds prevent and reverse established Th2-dominant immune responses in mice.
- the co-administration of IMO compounds with OVA/alum to mice reduces IL-4, IL-5, and IL-13 production and induces IFN- ⁇ production in spleen-cell cultures subjected to antigen re-stimulation.
- IMO compounds inhibit antigen-specific and total IgE and enhance IgG2a production in these mice.
- Injection of OVA/alum and IMO compounds induces a lymphocyte antigen-recall response (Th1-type) in mice characterized by low levels of Th2-associated cytokines, IgE and IgG1, and high levels of Th1-associated cytokines and IgG2a.
- Co-administration of IMO compounds with other kinds of antigens such as S. masoni egg and hen egg lysozyme, also result in reversal of the Th2-response to a Th1-dominant response in in vitro and in vivo studies.
- IMO compounds effectively prevent development of a Th2 immune response and allow a strong Th1 response.
- Th2 cytokines trigger an Ig isotype switch towards production of IgE and IgG1
- the Th1 cytokine IFN- ⁇ induces production of IgG2a by B-lymphocytes.
- Mice injected with OVA/alum and IMO compounds produce lower levels of IL-4, IL-5, and IL-13 and higher levels of IFN- ⁇ , accompanied by lower IgE and IgG1 and higher IgG2a levels, than mice injected with OVA/alum alone. This suggests the existence of a close link between Th1-cytokine induction and immunoglobulin isotype switch in mice that receive antigen and IMO compounds.
- Serum antigen-specific and total IgE levels are significantly lower in mice receiving OVA/alum and IMO compounds than in mice receiving OVA/alum alone.
- OVA-specific IgG1 levels are insignificantly changed and total IgG1 levels are only slightly decreased compared with mice injected with OVA/alum alone (data not shown).
- the different response may result from different mechanisms involved in the control of IgE and IgG1 class switch, though both isotypes are influenced by IL-4 and IL-13.
- IL-6 promotes B lymphocytes to synthesize IgG1 in the presence of IL-4.
- the invention provides a method for preventing cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen in a vertebrate.
- This method comprises administering to the vertebrate any one of the compositions, alone or in combination, disclosed in the first, second and third aspects of the invention.
- Pathogens include bacteria, parasites, fungi, viruses, viroids and prions. Administration is carried out as described for the fourth aspect of the invention.
- the immunostimulatory oligonucleotide and/or immunomer or a conjugate thereof can be administered in combination with any other agent useful for treating the disease or condition that does not diminish the immunostimulatory effect of the oligonucleotide or immunomer.
- the term “in combination with” means in the course of treating the same disease in the same patient, and includes administering the oligonucleotide and/or immunomer and an agent in any order, including simultaneous administration, as well as any temporally spaced order, for example, from sequentially with one immediately following the other to up to several days apart.
- Such combination treatment may also include more than a single administration of the immunomer, and independently the agent.
- the administration of the oligonucleotide and/or immunomer and agent may be by the same or different routes.
- the agent useful for treating the disease or condition includes, but is not limited to, vaccines, antigens, antibodies, cytotoxic agents, allergens, antibiotics, antisense oligonucleotides, peptides, proteins, gene therapy vectors, DNA vaccines and/or adjuvants to enhance the specificity or magnitude of the immune response, or co-stimulatory molecules such as cytokines, chemokines, protein ligands, trans-activating factors, peptides and peptides comprising modified amino acids.
- the agent can include DNA vectors encoding for antigen or allergen.
- the immunomers of the invention can variously act as adjuvants and/or produce direct immunostimulatory effects.
- CpG oligonucleotides (immunostimulatory oligonucleotides/immunomers) were synthesized on a 1 to 2 ⁇ mole scale using ⁇ -cyanoethylphosphoramidites on a PerSeptive Biosystem's 8909 Expedite DNA synthesizer (PerSeptive Biosystem, Boston, Mass.).
- the phosphoramidites of dA, dG, dC, and T were obtained from PE Biosystems (Foster City, Calif.). As described by Iyer R. P., et al. ( J. Am. Chem. Soc.
- oligos The purity of full-length oligos ranged from 90-96% with the rest being shorter by one or two nucleotides (n ⁇ 1 and n ⁇ 2) as determined by CGE and/or denaturing PAGE. All oligos contained less than ⁇ 0.1 EU/mL of endotoxin as determined by the Limulus assay (Bio-Whittaker now known as Cambrex Bio Science Walkersville, Inc., Walkersville, Md.).
- Thermal melting studies were carried out in 1 mL solution of 10 mM disodium hydrogen phosphate, pH 7.2 ⁇ 0.2, containing 150 mM NaCl, and 2 mM MgCl2. The solutions were heated to 95° C. for 10 min and allowed to come to room temperature slowly before being stored at 4° C. overnight. The final concentration of oligonucleotide strand was 2.0 ⁇ M.
- UV thermal melting measurements were performed at 260 nm on a Perkin-Elmer Lambda 20 Spectrophotometer attached to a peltier thermal controller and a personal computer using 1 cm path length quartz cuvettes at a heating rate of 0.5° C./min. Melting temperatures (Tm) were taken as the temperature of half-dissociation and were obtained from first derivative plots. Each Tm value is an average of two or three independent experiments and the values were within ⁇ 1.0° C.
- Spleen cells from 4-8 week old BALB/c, C57BL/6 or C3H/HeJ mice were cultured in RPMI complete medium as described by Zhao, Q., et al. ( Biochem Pharmacol. 51: 173-182 (1996)) and Branda, R. F., et al. ( Biochem. Pharmacol. 45: 2037-2043 (1993)).
- Murine J774 macrophages (American Type Culture Collection, University Boulevard, Manassas, Va. 20110-2209) were cultured in Dulbecco's modified Eagles medium supplemented with 10% (v/v) fetal calf serum and antibiotics (100 IU/mL of penicillin G/streptomycin). All other culture reagents were purchased from Mediatech (Gaithersburg, Md.).
- mouse (Balb-C) spleen cells were cultured with immunomer compounds at concentrations of 0.1, 1.0, and 10.0 ⁇ g/ml for 48 h and cell proliferation was determined by 3H-uridine incorporation, as described by Zhao, Q., et al. ( Biochem Pharmacol. 51: 173-182 (1996)).
- Mouse spleen or J774 cells were plated in 24-well dishes using 5 ⁇ 10 6 or 1 ⁇ 10 6 cells/mL, respectively.
- the immunomer compounds dissolved in TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) were added to a final concentration of 0.03, 0.1, 0.3, 1.0, 3.0, or 10.0 ⁇ g/mL to the cell cultures.
- the cells were then incubated at 37° C. for 24 hr and the supernatants were collected for ELISA assays.
- the experiments were performed two or three times for each immunomer compound and in triplicate for each concentration.
- the secretion of IL-12 and IL-6 was measured by sandwich ELISA as described by Bhagat L., et al. ( Biochem. Biophys. Res. Commun. 300: 853-861 (2003)).
- the required reagents, including cytokine antibodies and standards were purchased from BD Biosciences Pharmingen (San Diego
- mice Female BALB/c mice (4-6 weeks, 19-21 gm) were divided into groups of three mice. Immunomer compounds were dissolved in sterile phosphate buffered saline (PBS) and administered subcutaneously (SC) to mice at a dose of 5 mg/kg. The mice were sacrificed after 48 hr and the spleens were harvested and weighed as described by Zhao, Q., et al. ( Biochem Pharmacol. 51: 173-182 (1996)) and Branda, R. F., et al. ( Biochem. Pharmacol. 45: 2037-2043 (1993)).
- PBS sterile phosphate buffered saline
- SC subcutaneously
- Toll-like receptor 9 has been shown to recognize unmethylated CpG-dinucleotides in bacterial, plasmid and synthetic DNAs (Hemmi H., et al. Nature 408: 740-745 (2000)) and activate stress kinase (Yi A. K., et al. J. Immunol. 161: 4493-4497 (1998)) and NF- ⁇ B pathways (Stacey K. J., et al. J. Immunol. 157: 2116-2122 (1996)).
- NF- ⁇ B activation in J774 cells treated with immunomer compounds was carried out and analyzed by EMSA as described Yu D., et al. ( Biochem. Biophys. Res. Commun. 297: 83-90 (2002)) and Bhagat L., et al. ( Biochem. Biophys. Res. Commun. 300: 853-861 (2003)).
- PBMCs from freshly drawn healthy volunteer blood were isolated by Ficoll density gradient centrifugation method (Histopaque-1077, Sigma) and B cells were isolated from PBMCs by positive selection using the CD19 cell isolation kit (Miltenyi Biotec) according to the manufacturer's instructions.
- Table 1 shows the immunostimulatory activity of immunomer compounds of the invention in C57BL/6 Splenocyte Assay.
- G 1 2′-deoxy-7-deazaguanosine
- X Glycerol Linker
- Y C3 Linker
- pDCs were isolated from human PBMCs using a BDCA-4 cell isolation kit (Miltenyi Biotec) according to the manufacturer's instructions. pDC were plated in 96-well plates using 1 ⁇ 10 6 cells/mL, 200 ⁇ L/well). The immunomer compounds were added to a final concentration of 0.3, 1.0, 3.0, or 10.0 ⁇ g/mL to the cell cultures and incubated at 37° C. for 24 hr. Supernatants were then harvested and assayed for IFN- ⁇ and IFN- ⁇ using ELISA kit (PBL). Tables 2A-2D show an average ⁇ SD of IFN- ⁇ and IFN- ⁇ for immunomer compounds according to the invention at a concentration of 10.0 ⁇ g/mL.
- G 1 2′-deoxy-7-deazaguanosine
- G 2 Arabinoguanosine
- C 1 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine
- X Glycerol Linker
- Y C3 Linker
- the secretion of IFN- ⁇ in vertebrate cells was measured by sandwich ELISA.
- the required reagents including cytokine antibodies and cytokine standards were purchased form PharMingen, San Diego, Calif.
- ELISA plates (Costar) were incubated with appropriate antibodies at 5 ⁇ g/mL in PBSN buffer (PBS/0.05% sodium azide, pH 9.6) overnight at 4° C. and then blocked with PBS/1% BSA at 37° C. for 30 minutes.
- Cell culture supernatants and cytokine standards were appropriately diluted with PBS/10% FBS, added to the plates in triplicate, and incubated at 25° C. for 2 hours.
- Plates were overlaid with 1 ⁇ g/mL appropriate biotinylated antibody and incubated at 25° C. for 1.5 hours. The plates were then washed extensively with PBS-T Buffer (PBS/0.05% Tween 20) and further incubated at 25° C. for 1.5 hours after adding streptavidin conjugated peroxidase (Sigma, St. Louis, Mo.). The plates were developed with Sure BlueTM (Kirkegaard and Perry) chromogenic reagent and the reaction was terminated by adding Stop Solution (Kirkegaard and Perry). The color change was measured on a Ceres 900 HDI Spectrophotometer (Bio-Tek Instruments).
- PBMCs Human peripheral blood mononuclear cells
- the resulting cell pellet was then resuspended in RPMI 1640 medium containing L-glutamine (MediaTech, Inc., Herndon, Va.) and supplemented with 10% heat inactivated FCS and penicillin-streptomycin (100 U/ml).
- Cells were cultured in 24 well plates for different time periods at 1 ⁇ 10 6 cells/ml/well in the presence or absence of oligonucleotides.
- supernatants were harvested and stored frozen at ⁇ 70° C. until assayed for various cytokines including IFN- ⁇ (BioSource International) by sandwich ELISA. The results are shown in Table 3A-3D below.
- the levels of IFN- ⁇ in the cell culture supernatants was calculated from the standard curve constructed under the same experimental conditions for IFN- ⁇ .
- G 1 2′-deoxy-7-deazaguanosine
- G 2 Arabinoguanosine
- C 1 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine
- X Glycerol Linker
- Y C3 Linker
- Cell surface markers of CD69 and CD86 were detected with a Coulter Epics-XL Flow Cytometer using anti-human CD69-Fitc and CD86-Fitc, which were purchased from BD Pharmingen (San Diego, USA). Staining methods were briefly descried as follow.
- the activated culture cells were blocked with 10% Human AB serum (Sigma) in staining buffer (PBS with 1% BSA and 0.1% NaN 3 ) at 4° C. for 1 hour and stained with the antibodies at 4° C. overnight.
- PBMCs (4 ⁇ 10 5 ) were stained with CD69-Fitc and CD86-Fitc.
- PDCs (2 ⁇ 10 5 ) were stained CD86-Fitc.
- the cell staining data were acquired and analyzed with Coulter System II software (see Tables 4A-4F below).
- G 1 2′-deoxy-7-deazaguanosine
- G 2 Arabinoguanosine
- C 1 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine
- X Glycerol Linker
- Y C3 Linker
- G 1 2′-deoxy-7-deazaguanosine
- G 2 Arabinoguanosine
- C 1 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine
- X Glycerol Linker
- Y C3 Linker
- a total of 1 ⁇ 10 5 B cells/200 ⁇ l were stimulated with 0.3, 1.0, 3.0, or 10.0 ⁇ g/mL concentrations of immunomer compounds of the invention for 16 hr, then pulsed with 0.75 ⁇ Ci of [ 3 H]-thymidine and harvested 8 h later.
- the incorporation of radioactivity was measured using liquid scintillation counter.
- Table 5 shows an average ⁇ SD of B cell proliferation at a final concentration of 1.0 ⁇ g/mL.
- G 1 2′-deoxy-7-deazaguanosine
- G 2 Arabinoguanosine
- C 1 1-(2′-deoxy- ⁇ -D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine
- X Glycerol Linker
- Y C3 Linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
Description
- This application is a continuation-in-part of U.S. patent application Ser. No. 10/892,550, filed Jul. 15, 2004 and a continuation of U.S. patent application Ser. No. 11/153,054, filed Jun. 15, 2005, which claims the benefit of U.S. Provisional Application Ser. No. 60/579,985, filed Jun. 15, 2004, and U.S. Provisional Application Ser. No. 60/599,362, filed on Aug. 6, 2004. The entire teachings of the above-referenced Applications are incorporated herein by reference.
- 1. Field of the Invention
- The invention relates to immune stimulation by oligonucleotide analogs.
- 2. Summary of the Related Art
- Tokunaga et al., J. Natl. Cancer Inst. 72 (1984) 955-96; Pisetsky et al.; Reich et al., Mol. Biol. Rep. 18 (1993) 217-221; Krieg et al., Yi et al., Nature 374 (1995) 546-549 and Sato et al., Science 273 (1996) 352-354 teach that bacterial DNA, synthetic oligodeoxynucleotides, and DNA vaccines containing unmethylated CpG-dinucleotides in specific sequence contexts (CpG DNA) activate the vertebrate immune system.
- Krieg et al., Annu. Rev. Immunol. 20 (2002) 709-760; Dalpke et al., Biol. Chem. 383 (2002) 1491-1500 and Kandimalla et al., Curr. Opin. Mol. Ther. 4 (2002) 122-129 teach that CpG DNAs induce innate immune cells to produce Th1 cytokines that promote cytotoxic T lymphocyte (CTL) responses and production of immunoglobulins by B cells. The immunostimulatory properties of CpG DNAs have allowed their use as therapeutic agents for a broad spectrum of disease indications including cancers, viral and bacterial infections, inflammatory disorders and as adjuvant in immunotherapy.
- In addition to chemical modifications, a number of structural modifications influenced the activity of CpG DNAs. Kandimalla et al., Nucleic Acids Res. 30 (2002) 4460-4469 teaches that CpG DNAs that contained two freely accessible 5′-ends through a 3′-3′-linkage had greater activity than did conventional CpG DNAs containing multiple copies of CpG motifs and a single 5′-end.
- Kandimalla et al, Biochem. Biophys. Res. Commun. 306 (2003) 948-953 teaches that the presence of a secondary structure in CpG DNAs significantly affected their activity depending on the position and nature of the secondary structure, that the presence of a hairpin structure at the 5′-end abrogated stimulatory activity, and that the same structure at the 3′-end had an insignificant effect on stimulatory activity but caused lower IL-6 secretion and contributed to higher stability against nucleases.
- There remains a need to “customize” the immune response through modification of oligonucleotide analogs.
- In a first aspect the invention provides an immunostimulatory oligonucleotide the sequence of which is at least partially self-complementary. The immunostimulatory nucleic acid comprises an oligonucleotide sequence containing at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-dideoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy-5-hydroxycytidine, 2′-deoxy-N4-alkyl-cytidine, 2′-deoxy-4-thiouridine, or other pyrimidine nucleoside analogs, G* is 2′-deoxy-7-deazaguanosine, 2′-deoxy-6-thioguanosine, arabinoguanosine, 2′-deoxy-2′substituted-arabinoguanosine, 2′-O-substituted-arabinoguanosine, 2′-deoxyinosine, or other purine nucleoside analogs, and p is an internucleoside linkage selected from the group consisting of phosphodiester, phosphorothioate, and phosphorodithioate.
- In some embodiments, the immunostimulatory nucleic acid is from about 2 to about 50 nucleotides in length. In certain embodiments the immunostimulatory nucleic acid is from about 12 to about 26 nucleotides in length. In some embodiments, the oligonucleotides each have from about 3 to about 35 nucleoside residues, in further embodiments from about 4 to about 30 nucleoside residues, in even further embodiments from about 4 to about 20 nucleoside residues. In some embodiments, the oligonucleotides have from about 5 to about 18, or from about 5 to about 14, nucleoside residues. As used herein, the term “about” implies that the exact number is not critical. Thus, the number of nucleoside residues in the oligonucleotides is not critical, and oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above. In some embodiments, one or more of the oligonucleotides have 11 nucleotides.
- In a second aspect the invention provides an immunomer comprising at least two oligonucleotides linked by a non-nucleotide linker, wherein the sequences of the immunostimulatory oligonucleotides are at least partially self-complementary. In certain embodiments according to this aspect of the invention at least one of the oligonucleotides contains at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-dideoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy-5-hydroxycytidine, 2′-deoxy-N4-alkyl-cytidine, 2′-deoxy-4-thiouridine, or other pyrimidine nucleoside analogs, G* is 2′-deoxy-7-deazaguanosine, 2′-deoxy-6-thioguanosine, arabinoguanosine, 2′-deoxy-2′substituted-arabinoguanosine, 2′-O-substituted-arabinoguanosine, 2′-deoxyinosine, or other purine nucleoside analogs, and p is an internucleoside linkage selected from the group consisting of phosphodiester, phosphorothioate, and phosphorodithioate.
- In some embodiments, the immunostimulatory nucleic acid is from about 2 to about 50 nucleotides in length. In certain embodiments the immunostimulatory nucleic acid is from about 12 to about 26 nucleotides in length. In some embodiments, the oligonucleotides each have from about 3 to about 35 nucleoside residues, or from about 4 to about 30 nucleoside residues, or from about 4 to about 20 nucleoside residues. In some embodiments, the oligonucleotides have from about 5 to about 18, or from about 5 to about 14, nucleoside residues. As used herein, the term “about” implies that the exact number is not critical. Thus, the number of nucleoside residues in the oligonucleotides is not critical, and oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above. In some embodiments, one or more of the oligonucleotides have 11 nucleotides.
- In a third aspect the invention provides pharmaceutical compositions. These compositions comprise any one of the compositions disclosed in the first and second aspects of the invention either alone or in combination and a pharmaceutically acceptable carrier.
- In a fourth aspect the invention provides a method for generating an immune response in a vertebrate. This method comprises administering to the vertebrate any one of the compositions, alone or in combination, disclosed in the first, second and third aspects of the invention. The compositions disclosed herein can be administered through any suitable route of administration including, but not limited to, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash.
- In a fifth aspect the invention provides a method for therapeutically treating a vertebrate having cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen. This method comprises administering to the vertebrate any one of the compositions, alone or in combination, disclosed in the first, second and third aspects of the invention. The compositions disclosed herein can be administered through any suitable route of administration including, but not limited to, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop, ear drop and mouthwash.
- In a sixth aspect the invention provides a method for preventing cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen in a vertebrate. This method comprises administering to the vertebrate any one of the compositions, alone or in combination, disclosed in the first, second and third aspects of the invention. The compositions disclosed herein can be administered through any suitable route of administration including, but not limited to, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop, ear drop and mouthwash.
-
FIGS. 1A and 1B are representations of various embodiments of the invention. InFIG. 1B , m and n are independently 0-1000 (SEQ ID NO 41). -
FIG. 2 is a synthetic scheme for the parallel synthesis of immunomers of the invention. DMTr=4,4′-dimethoxytrityl; CE=cyanoethyl. -
FIG. 3 depicts a group of representative small molecule linkers suitable for linear synthesis of immunomers of the invention. -
FIG. 4 is a synthetic scheme for the linear synthesis of immunomers of the invention. DMTr=4,4′-dimethoxytrityl; CE=cyanoethyl. -
FIG. 5 depicts a group of representative small molecule linkers suitable for parallel synthesis of immunomers of the invention. - The issued patents, patent applications, and references that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference. In the event of inconsistencies between any teaching of any reference cited herein and the present specification, the latter shall prevail for purposes of the invention.
- The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents for immunotherapy applications. The invention also provides methods for generating, enhancing and modifying the immune response caused by immunostimulatory compounds used for immunotherapy applications such as, but not limited to, treatment and/or prevention of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies, and bacteria, parasitic, and viral infections in adult and pediatric human and veterinary applications. Allergic asthma is a certain embodied condition for treatment by the present methods and compounds. Thus, the invention further provides compounds having optimal levels of immunostimulatory effect for immunotherapy and methods for making and using such compounds. In addition, immunostimulatory oligonucleotides/immunomers of the invention are useful as adjuvants in combination with DNA vaccines, antibodies, allergens, chemotherapeutic agents, and antisense oligonucleotides.
- In a first aspect the invention provides an immunostimulatory oligonucleotide the sequence of which is at least partially self-complementary. The immunostimulatory nucleic acid comprises an nucleic acid sequence containing at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-dideoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy-5-hydroxycytidine, 2′-deoxy-N4-alkyl-cytidine, 2′-deoxy-4-thiouridine, or other pyrimidine nucleoside analogs, G* is 2′-deoxy-7-deazaguanosine, 2′-deoxy-6-thioguanosine, arabinoguanosine, 2′-deoxy-2′substituted-arabinoguanosine, 2′-O-substituted-arabinoguanosine, 2′-deoxyinosine, or other purine nucleoside analogs, and p is an internucleoside linkage selected from the group consisting of phosphodiester, phosphorothioate, and phosphorodithioate.
- In some embodiments, the immunostimulatory oligonucleotide is from about 2 to about 50 nucleotides in length. In certain embodiments the immunostimulatory oligonucleotide is from about 12 to about 26 nucleotides in length. In some embodiments, the oligonucleotides are from about 3 to about 35 nucleoside residues, or from about 4 to about 30 nucleoside residues, or from about 4 to about 20 nucleoside residues. In some embodiments, the oligonucleotides have from about 5 to about 18, or from about 5 to about 14, nucleoside residues. As used herein, the term “about” implies that the exact number is not critical. Thus, the number of nucleoside residues in the oligonucleotides is not critical, and oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above. In some embodiments, one or more of the oligonucleotides have 11 nucleotides.
- As would be recognized by one skilled in the art, the complementary sequence of the oligonucleotides allows for intermolecular hydrogen bonding thereby giving the oligonucleotides secondary structure. Additional oligonucleotides can bind together thereby creating a chain, or multimers, of oligonucleotides according to the invention.
- In a second aspect the invention provides an immunomer comprising at least two oligonucleotides linked by a non-nucleotide linker, wherein the sequences of the immunostimulatory oligonucleotides are at least partially self-complementary. In certain embodiments according to this aspect of the invention at least one of the oligonucleotides contains at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-dideoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy-5-hydroxycytidine, 2′-deoxy-N4-alkyl-cytidine, 2′-deoxy-4-thiouridine, or other pyrimidine nucleoside analogs, G* is 2′-deoxy-7-deazaguanosine, 2′-deoxy-6-thioguanosine, arabinoguanosine, 2′-deoxy-2′substituted-arabinoguanosine, 2′-O-substituted-arabinoguanosine, 2′-deoxyinosine, or other purine nucleoside analogs, and p is an internucleoside linkage selected from the group consisting of phosphodiester, phosphorothioate, and phosphorodithioate.
- In this aspect, immunostimulatory nucleic acid comprises a structure as detailed in formula (I).
-
Domain A-Domain B-Domain C (I) - Domains may be from about 2 to about 12 nucleotides in length. Domain A may be 5′-3′ or 3′-5′ or 2′-5′ DNA, RNA, RNA-DNA, DNA-RNA having a palindromic or self-complementary domain containing or not containing at least one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-deoxy-5-halocytosine, 2′-deoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy-5-hydroxycytidine, 2′-deoxy-N4-alkyl-cytidine, 2′-deoxy-4-thiouridine, or other pyrimidine nucleoside analogs, G* is 2′-deoxy-7-deazaguanosine, 2′-deoxy-6-thioguanosine, arabinoguanosine, 2′-deoxy-2′substituted-arabinoguanosine, 2′-O-substituted-arabinoguanosine, 2′-deoxyinosine, or other purine nucleoside analogs, and p is an internucleoside linkage selected from the group consisting of phosphodiester, phosphorothioate, and phosphorodithioate. In certain embodiments, the immunostimulatory dinucleotide is not CpG.
- In certain embodiments, Domain A will have more than one dinucleotide selected from the group consisting of CpG, C*pG, C*pG* and CpG*.
- Domain B, as depicted by an “X” below, is a linker joining Domains A and C that may be a 3′-′5′ linkage, a 2′-5′ linkage, a 3′-3′ linkage, a phosphate group, a nucleoside, or a non-nucleoside linker that may be aliphatic, aromatic, aryl, cyclic, chiral, achiral, a peptide, a carbohydrate, a lipid, a fatty acid, mono- tri- or hexapolyethylene glycol, or a heterocyclic moiety.
- Domain C may be 5′-3′ or 3′-5′,2′-5′ DNA, RNA, RNA-DNA, DNA-RNA Poly I-Poly C having a palindromic or self-complementary sequence, containing or not containing a dinucleotide selected from the group consisting of CpG, C*pG, C*pG*, CpG*, wherein C is cytidine or 2′-deoxycytidine, G is guanosine or 2′-deoxyguanosine, C* is 2′-deoxythymidine, 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine, 2′-deoxy-5-halocytosine, 2′-dideoxy-5-nitrocytosine, arabinocytidine, 2′-deoxy-2′-substituted arabinocytidine, 2′-O-substituted arabinocytidine, 2′-deoxy-5-hydroxycytidine, 2′-deoxy-N4-alkyl-cytidine, 2′-deoxy-4-thiouridine, other pyrimidine nucleoside analogs, G* is 2′-deoxy-7-deazaguanosine, 2′-deoxy-6-thioguanosine, arabinoguanosine, 2′-deoxy-2′substituted-arabinoguanosine, 2′-O-substituted-arabinoguanosine, 2′-deoxyinosine, or other purine nucleoside analogs, and p is an internucleoside linkage selected from the group consisting of phosphodiester, phosphorothioate, and phosphorodithioate. In certain embodiments, the immunostimulatory dinucleotide is not CpG. In some embodiments, Domain B is preferably a non-nucleotidic linker connecting oligonucleotides of Domain A and Domain C, which are referred to as “immunomers.” In certain embodiments, Domain C does not have the dinucleotide CpG, C*pG, C*pG* or CpG*.
- In some embodiments, the oligonucleotides contained in formula (I) are from about 2 to about 50 nucleotides in length. In certain embodiments the oligonucleotides contained in formula (I) are from about 12 to about 26 nucleotides in length. In some embodiments, the oligonucleotides each have from about 3 to about 35 nucleoside residues, preferably from about 4 to about 30 nucleoside residues, more preferably from about 4 to about 20 nucleoside residues. In some embodiments, the oligonucleotides have from about 5 to about 18, or from about 5 to about 14, nucleoside residues. As used herein, the term “about” implies that the exact number is not critical. Thus, the number of nucleoside residues in the oligonucleotides is not critical, and oligonucleotides having one or two fewer nucleoside residues, or from one to several additional nucleoside residues are contemplated as equivalents of each of the embodiments described above. In some embodiments, one or more of the oligonucleotides have 11 nucleotides.
- A self-complementary sequence as used herein refers to a base sequence which, upon suitable alignment, may form intramolecular or, more typically, intermolecular basepairing between G-C, A-T, A-U and/or G-U wobble pairs. In one embodiment the extent of self-complementarity is at least 50 percent. For example an 8-mer that is at least 50 percent self-complementary may have a sequence capable of forming 4, 5, 6, 7, or 8 G-C, A-T, A-U and/or G-U wobble basepairs. Such basepairs may but need not necessarily involve bases located at either end of the self-complementary immunostimulatory oligonucleotide and/or immunomer. Where nucleic acid stabilization may be important to the immunostimulatory oligonucleotide and/or immunomer, it may be advantageous to “clamp” together one or both ends of a double-stranded nucleic acid, either by basepairing or by any other suitable means. The degree of self-complementarity may depend on the alignment between immunostimulatory oligonucleotide and/or immunomer, and such alignment may or may not include single- or multiple-nucleoside overhangs. In other embodiments, the degree of self-complementarity is at least 60 percent, at least 70 percent, at least 80 percent, at least 90 percent, or even 100 percent.
- Similar considerations apply to intermolecular basepairing between immunostimulatory oligonucleotides and/or immunomers of different base sequence. Thus, where a plurality of immunostimulatory oligonucleotides and/or immunomers are used together, the plurality of immunostimulatory oligonucleotides and/or immunomers may, but need not, include sequences which are at least partially complementary to one another. In one embodiment the plurality of immunostimulatory oligonucleotides and/or immunomers includes an immunostimulatory oligonucleotide and/or immunomer having a first sequence and an immunostimulatory oligonucleotide and/or immunomer having a second sequence, wherein the first sequence and the second sequence are at least 50 percent complementary. For example, as between two 8-mers that are at least 50 percent complementary, they may form 4, 5, 6, 7, or 8 G-C, A-T, A-U, and/or G-U wobble basepairs. Such basepairs may but need not necessarily involve bases located at either end of the complementary immunostimulatory oligonucleotides and/or immunomers. The degree of complementarity may depend on the alignment between immunostimulatory oligonucleotides and/or immunomers, and such alignment may or may not include single- or multiple-nucleoside overhangs. In other embodiments, the degree of complementarity is at least 60 percent, at least 70 percent, at least 80 percent, at least 90 percent, or even 100 percent.
- By way of non-limiting example, in certain embodiments of this aspect the immunostimulatory nucleic acid will have a structure as detailed in formula (II).
- As would be recognized by one skilled in the art, the depicted immunostimulatory nucleic acid/immunomer compounds have secondary structure because the sequences of the domains are complementary allowing for intermolecular hydrogen bonding. Domains A and A′ may or may not be identical, domains A and C may or may not be identical, domains A and C′ may or may not be identical, domains A′ and C may or may not be identical, domains A′ and C′ may or may not be identical, domains B and B′ may or may not be identical and domains C and C′ may or may not be identical. Moreover, as shown in
FIG. 1 , additional immunomers can bind through intermolecular hydrogen bonding thereby creating a chain, or multimers, of immunomers according to the invention. n can be any number of continuous, self complementary immunomer compounds. - As used herein, the term “complementary” means having the ability to hybridize to a nucleic acid. Such hybridization is ordinarily the result of hydrogen bonding between complementary strands, preferably to form Watson-Crick or Hoogsteen base pairs, although other modes of hydrogen bonding, as well as base stacking can also lead to hybridization.
- As used herein, the term “secondary structure” refers to intermolecular hydrogen bonding. Intermolecular hydrogen bonding results in the formation of a duplexed nucleic acid molecule.
- “Palindromic sequence” shall mean an inverted repeat (i.e., a sequence such as ABCDEE′D′C′B′A′ in which A and A′, B and B′, etc., are bases capable of forming the usual Watson-Crick base pairs. In vivo, such sequences may form double-stranded structures. In one embodiment the CpG nucleic acid contains a palindromic sequence. A palindromic sequence used in this context refers to a palindrome in which the CpG is part of the palindrome. In some embodiments the CpG is the center of the palindrome. In another embodiment the CpG nucleic acid is free of a palindrome. An immunostimulatory nucleic acid that is free of a palindrome is one in which the CpG dinucleotide is not part of a palindrome. Such an oligonucleotide may include a palindrome in which the CpG is not the center of the palindrome.
- For purposes of the invention, the term “oligonucleotide” refers to a polynucleoside formed from a plurality of linked nucleoside units. Such oligonucleotides can be obtained from existing nucleic acid sources, including genomic or cDNA, but are preferably produced by synthetic methods. In some embodiments each nucleoside unit includes a heterocyclic base and a pentofuranosyl, 2′-deoxypentfuranosyl, trehalose, arabinose, 2′-deoxy-2′-substituted arabinose, 2′-O-substituted arabinose or hexose sugar group. The nucleoside residues can be coupled to each other by any of the numerous known internucleoside linkages. Such internucleoside linkages include, without limitation, phosphodiester, phosphorothioate, phosphorodithioate, alkylphosphonate, alkylphosphonothioate, phosphotriester, phosphoramidate, siloxane, carbonate, carboalkoxy, acetamidate, carbamate, morpholino, borano, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphorothioate, and sulfone internucleoside linkages. The term “oligonucleotide” also encompasses polynucleosides having one or more stereospecific internucleoside linkage (e.g., (RP)- or (SP)-phosphorothioate, alkylphosphonate, or phosphotriester linkages). As used herein, the terms “oligonucleotide” and “dinucleotide” are expressly intended to include polynucleosides and dinucleosides having any such internucleoside linkage, whether or not the linkage comprises a phosphate group. In certain embodiments, these internucleoside linkages may be phosphodiester, phosphorothioate, or phosphorodithioate linkages, or combinations thereof.
- The term “oligonucleotide” also encompasses polynucleosides having additional substituents including, without limitation, protein groups, lipophilic groups, intercalating agents, diamines, folic acid, cholesterol and adamantane. The term “oligonucleotide” also encompasses any other nucleobase containing polymer, including, without limitation, peptide nucleic acids (PNA), peptide nucleic acids with phosphate groups (PHONA), locked nucleic acids (LNA), morpholino-backbone oligonucleotides, and oligonucleotides having backbone sections with alkyl linkers or amino linkers.
- The oligonucleotides of the invention can include naturally occurring nucleosides, modified nucleosides, or mixtures thereof. As used herein, the term “modified nucleoside” is a nucleoside that includes a modified heterocyclic base, a modified sugar moiety, or a combination thereof. In some embodiments, the modified nucleoside is a non-natural pyrimidine or purine nucleoside, as herein described. In some embodiments, the modified nucleoside is a 2′-substituted ribonucleoside an arabinonucleoside or a 2′-deoxy-2′-substituted-arabinoside.
- For purposes of the invention, the term “2′-substituted ribonucleoside” or “2′-substituted arabinoside” includes ribonucleosides or arabinonucleosides in which the hydroxyl group at the 2′ position of the pentose moiety is substituted to produce a 2′-substituted or 2′-O-substituted ribonucleoside. In certain embodiments, such substitution is with a lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an aryl group having 6-10 carbon atoms, wherein such alkyl, or aryl group may be unsubstituted or may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carboalkoxy, or amino groups. Examples of 2′-O-substituted ribonucleosides or 2′-O-substituted-arabinosides include, without
limitation 2′-O-methylribonucleosides or 2′-O-methylarabinosides and 2′-O-methoxyethoxyribonucleosides or 2′-O-methoxyethoxyarabinosides. - The term “2′-substituted ribonucleoside” or “2′-substituted arabinoside” also includes ribonucleosides or arabinonucleosides in which the 2′-hydroxyl group is replaced with a lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an amino or halo group. Examples of such 2′-substituted ribonucleosides or 2′-substituted arabinosides include, without limitation, 2′-amino, 2′-fluoro, 2′-allyl, and 2′-propargyl ribonucleosides or arabinosides.
- The term “oligonucleotide” includes hybrid and chimeric oligonucleotides. A “chimeric oligonucleotide” is an oligonucleotide having more than one type of internucleoside linkage. One non-limiting example of such a chimeric oligonucleotide is a chimeric oligonucleotide comprising a phosphorothioate, phosphodiester or phosphorodithioate region and non-ionic linkages such as alkylphosphonate or alkylphosphonothioate linkages (see e.g., Pederson et al. U.S. Pat. Nos. 5,635,377 and 5,366,878).
- A “hybrid oligonucleotide” is an oligonucleotide having more than one type of nucleoside. One non-limiting example of such a hybrid oligonucleotide comprises a ribonucleotide or 2′ substituted ribonucleotide region, and a deoxyribonucleotide region (see, e.g., Metelev and Agrawal, U.S. Pat. Nos. 5,652,355, 6,346,614 and 6,143,881).
- Alternatively, the nucleic acid molecule of the invention can be two immunomers linked by way of a non-nucleotidic linker.
- In certain embodiments of the invention, at least one immunostimulatory oligonucleotide of the invention comprises an immunostimulatory dinucleotide of the
formula 5′-Pyr-Pur-3′, wherein Pyr is a natural pyrimidine nucleoside or analog thereof and Pur is a natural purine nucleoside or analog thereof. As used herein, the term “pyrimidine nucleoside” refers to a nucleoside wherein the base component of the nucleoside is a pyrimidine base. Similarly, the term “purine nucleoside” refers to a nucleoside wherein the base component of the nucleoside is a purine base. For purposes of the invention, a “synthetic” pyrimidine or purine nucleoside includes a non-naturally occurring pyrimidine or purine base, a non-naturally occurring sugar moiety, or a combination thereof. - In certain embodiments pyrimidine nucleosides in the immunostimulatory oligonucleotides and/or immunomers used in the method according to the invention have the structure (III):
- wherein:
- D is a hydrogen bond donor;
- D′ is selected from the group consisting of hydrogen, hydrogen bond donor, hydrogen bond acceptor, hydrophilic group, hydrophobic group, electron withdrawing group and electron donating group;
- A is a hydrogen bond acceptor or a hydrophilic group;
- A′ is selected from the group consisting of hydrogen bond acceptor, hydrophilic group, hydrophobic group, electron withdrawing group and electron donating group;
- X is carbon or nitrogen; and
- S′ is a pentose or hexose sugar ring, or a non-naturally occurring sugar.
- In certain embodiments, the sugar ring is derivatized with a phosphate moiety, modified phosphate moiety, or other linker moiety suitable for linking the pyrimidine nucleoside to another nucleoside or nucleoside analog.
- In some embodiments hydrogen bond donors include, without limitation, —NH—, —NH2, —SH and —OH. Preferred hydrogen bond acceptors include, without limitation, C═O, C═S, and the ring nitrogen atoms of an aromatic heterocycle, e.g., N3 of cytosine.
- In some embodiments, the base moiety in (III) is a non-naturally occurring pyrimidine base. Examples of preferred non-naturally occurring pyrimidine bases include, without limitation, 5-hydroxycytosine, 5-hydroxymethylcytosine, N4-alkylcytosine, or N4-ethylcytosine, and 4-thiouracil. In some embodiments, the sugar moiety S′ in (III) is a non-naturally occurring sugar moiety. For purposes of the present invention, a “naturally occurring sugar moiety” is a sugar moiety that occurs naturally as part of nucleic acid, e.g., ribose and 2′-deoxyribose and a “non-naturally occurring sugar moiety” is any sugar that does not occur naturally as part of a nucleic acid, but which can be used in the backbone for an oligonucleotide, e.g, hexose. Arabinose and arabinose derivatives are non-limiting examples of sugar moieties.
- In some embodiments purine nucleoside analogs in immunostimulatory oligonucleotides and/or immunomers used in the method according to the invention have the structure (IV):
- wherein:
- D is a hydrogen bond donor;
- D′ is selected from the group consisting of hydrogen, hydrogen bond donor, and hydrophilic group;
- A is a hydrogen bond acceptor or a hydrophilic group;
- X is carbon or nitrogen;
- each L is independently selected from the group consisting of C, O, N and S; and
- S′ is a pentose or hexose sugar ring, or a non-naturally occurring sugar.
- In certain embodiments, the sugar ring is derivatized with a phosphate moiety, modified phosphate moiety, or other linker moiety suitable for linking the pyrimidine nucleoside to another nucleoside or nucleoside analog.
- In certain embodiments hydrogen bond donors include, without limitation, —NH—, —NH2, —SH and —OH. Preferred hydrogen bond acceptors include, without limitation, C═O, C═S, —NO2 and the ring nitrogen atoms of an aromatic heterocycle, e.g., N1 of guanine.
- In some embodiments, the base moiety in (IV) is a non-naturally occurring purine base. Examples of preferred non-naturally occurring purine bases include, without limitation, 6-thioguanine and 7-deazaguanine. In some embodiments, the sugar moiety S′ in (IV) is a naturally occurring sugar moiety, as described above for structure (III).
- In a third aspect the invention provides pharmaceutical compositions. These compositions comprise any one of the compositions disclosed in the first and second of the invention either alone or in combination and a physiologically acceptable carrier.
- As used herein, the term “physiologically acceptable” refers to a material that does not interfere with the effectiveness of the compositions of the first, second or third aspects of the invention and is compatible with a biological system such as a cell, cell culture, tissue, or organism. In certain embodiments, the biological system is a living organism, such as a vertebrate.
- As used herein, the term “carrier” encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, or other material well known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient, or diluent will depend on the route of administration for a particular application. The preparation of pharmaceutically acceptable formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990, ISBN: 0-912734-04-3.
- Pharmaceutical compositions of the invention may also include a cancer vaccine, including a cancer vaccine selected from EFG, Anti-idiotypic cancer vaccines, Gp75 antigen, GMK melanoma vaccine, MGV ganglioside conjugate vaccine, Her2/new, Ovarex®, M-Vax, O-Vax, L-Vax, STn-KHL Theratope®, BLP25 (MUC-1), liposomal idiotypic vaccine, Melacine®, peptide antigen vaccines, toxin/antigen vaccines, MVA-vased vaccine, PACIS, BCG vaccine, TA-HPV, TA-CIN, DISC-virus and ImmunCyst/TheraCys®.
- In various embodiments of the invention, the compositions of the first, second or third aspects of the invention may be covalently linked to an antigen or otherwise operatively associated with an antigen. As used herein, the term “operatively associated with” refers to any association that maintains the activity of both the compositions of the first, second or third aspects of the invention and the antigen. Non-limiting examples of such operative associations include being part of the same liposome or other such delivery vehicle or reagent. In embodiments wherein the compositions of the first, second or third aspects of the invention are covalently linked to an antigen, such covalent linkage is at any position on the compositions of the first, second or third aspects of the invention other than an accessible 5′ end of an immunostimulatory oligonucleotide. For example, the antigen may be attached at an internucleoside linkage or may be attached to the non-nucleotidic linker. Alternatively, the antigen may itself be the non-nucleotidic linker.
- In various embodiments of the invention, the compositions of the first, second or third aspects of the invention may include an oligonucleotide with antisense activity. As used herein, “antisense activity” means that the oligonucleotide, when introduced into a cell or an animal, causes a reduction in the expression of the gene to which it is complementary.
- In various embodiments of the invention, the compositions of the first, second or third aspects of the invention may include an oligonucleotide sequence that is an aptamer. Aptamers are nucleic acid molecules that have been selected from random pools based on their ability to bind other molecules. Aptamers have been selected which bind nucleic acids, proteins, small organic compounds, and even entire organisms. These novel molecules have many potential uses in medicine and technology (see, e.g., Burgstaller P., et al. Curr Opin Drug Discov Devel. 5: 690-700 (2002)).
- The pharmaceutical compositions of the invention may be administered by any suitable route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form. The pharmaceutical compositions can be delivered using known procedures at dosages and for periods of time effective obtain the desired effect, e.g. the treatment of cancer, the treatment of infection and the treatment of autoimmune diseases. When administered systemically, the pharmaceutical compositions are administered at a sufficient dosage to attain a blood level of the compositions of the first, second and/or third aspects of the invention from about 0.0001 micromolar to about 10 micromolar. For localized administration, much lower concentrations than this may be effective, and much higher concentrations may be tolerated. In certain embodiments, a total dosage of immunostimulatory oligonucleotide and/or immunomer ranges from about 0.0001 mg per patient per day to about 200 mg per kg body weight per day. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
- Immunostimulatory oligonucleotides were created as immunomers using the following protocols for synthesis. The immunostimulatory oligonucleotides and/or immunomers of the invention may conveniently be synthesized using an automated synthesizer and phosphoramidite approach as schematically depicted in
FIGS. 2 and 4 . In some embodiments, the immunostimulatory oligonucleotides and/or immunomers are synthesized by a linear synthesis approach (seeFIG. 2 ). Representative linkers for this synthesis are presented inFIG. 3 . As used herein, the term “linear synthesis” refers to a synthesis that starts at one end of the immunomer and progresses linearly to the other end. Linear synthesis permits incorporation of either identical or un-identical (in terms of length, base composition and/or chemical modifications incorporated) monomeric units into the immunostimulatory oligonucleotides and/or immunomers. - An alternative mode of synthesis for immunostimulatory oligonucleotides and/or immunomers is “parallel synthesis”, in which synthesis proceeds outward from a central linker moiety (see
FIG. 4 ). Representative linkers for this method of synthesis are presented inFIG. 5 . A solid support attached linker can be used for parallel synthesis, as is described in U.S. Pat. No. 5,912,332. Alternatively, a universal solid support, such as phosphate attached to controlled pore glass support, can be used. - Parallel synthesis of immunostimulatory oligonucleotides and/or immunomers has several advantages over linear synthesis: (1) parallel synthesis permits the incorporation of identical monomeric units; (2) unlike in linear synthesis, both (or all) the monomeric units are synthesized at the same time, thereby the number of synthetic steps and the time required for the synthesis is the same as that of a monomeric unit; and (3) the reduction in synthetic steps improves purity and yield of the final immunomer product.
- At the end of the synthesis by either linear synthesis or parallel synthesis protocols, the immunostimulatory oligonucleotides or immunomers according to the invention may conveniently be deprotected with concentrated ammonia solution or as recommended by the phosphoramidite supplier, if a modified nucleoside is incorporated. The product immunostimulatory oligonucleotides and/or immunomer is preferably purified by reversed phase HPLC, detritylated, desalted and dialyzed.
- The compositions disclosed in the first second and third aspects of the invention can comprise the immunostimulatory oligonucleotide or immunomer alone or as oligonucleotide/immunomer conjugates. An oligonucleotide/immunomer conjugate comprises an oligonucleotide or immunomer, as described above, and an antigen conjugated to the oligonucleotide and/or immunomer at a position other than the accessible 5′ end. In some embodiments, the non-nucleotidic linker comprises an antigen, which is conjugated to the oligonucleotide. In some other embodiments, the antigen is conjugated to the oligonucleotide at a position other than its 3′ end. In some embodiments, the antigen produces a vaccine effect. The immunostimulatory oligonucleotide or immunomer alone or as oligonucleotide/immunomer conjugates can be administered in the methods discussed below.
- The antigen is optionally selected from antigens associated with a pathogen, antigens associated with a cancer, antigens associated with an auto-immune disorder, and antigens associated with other diseases such as, but not limited to, veterinary or pediatric diseases, or wherein the antigen is an allergen. For purposes of the invention, the term “associated with” means that the antigen is present when the pathogen, cancer, auto-immune disorder, food allergy, skin allergy, respiratory allergy, asthma or other disease is present, but either is not present, or is present in reduced amounts, when the pathogen, cancer, auto-immune disorder, food allergy, skin allergy, respiratory allergy, or disease is absent.
- The immunomer is covalently linked to the antigen, or it is otherwise operatively associated with the antigen. As used herein, the term “operatively associated with” refers to any association that maintains the activity of both immunomer and antigen. Nonlimiting examples of such operative associations include being part of the same liposome or other such delivery vehicle or reagent. In embodiments wherein the immunomer is covalently linked to the antigen, such covalent linkage preferably is at any position on the immunomer other than an accessible 5′ end of an immunostimulatory oligonucleotide. For example, the antigen may be attached at an internucleoside linkage or may be attached to the non-nucleotidic linker. Alternatively, the antigen may itself be the non-nucleotidic linker.
- In a fourth aspect, the invention provides methods for generating and/or modulating an immune response in a vertebrate, such methods comprising administering to the vertebrate an immunomer or immunomer conjugate according to the invention. In some embodiments, the vertebrate is a mammal. For purposes of this invention, the term “mammal” is expressly intended to include humans. In certain embodiments, the immunomer or immunomer conjugate is administered to a vertebrate in need of immunostimulation.
- As used herein, the term “modulating” or “modulate” means to increase or decrease the immunostimulatory activity of an immunostimulatory nucleic acid relative to that of the parent immunostimulatory nucleic acid.
- In the methods according to this aspect of the invention, administration of immunomers can be by any suitable route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, intramuscular, intraperitonal, subcutaneous, intradermal, aerosol, intraocular, intratracheal, intrarectal, vaginal, by gene gun, dermal patch or in eye drop or mouthwash form. Administration of the therapeutic compositions of immunomers can be carried out using known procedures at dosages and for periods of time effective to reduce symptoms or surrogate markers of the disease. When administered systemically, the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of immunomer from about 0.0001 micromolar to about 10 micromolar. For localized administration, much lower concentrations than this may be effective, and much higher concentrations may be tolerated. Preferably, a total dosage of immunomer ranges from about 0.001 mg per patient per day to about 200 mg per kg body weight per day. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
- Either the immunomer or the vaccine, or both, may optionally be linked to an immunogenic protein, such as keyhole limpet hemocyanin (KLH), cholera toxin B subunit, or any other immunogenic carrier protein or nonimmunogenic carrier protein. Any of the plethora of adjuvants may be used including, without limitation, Freund's complete adjuvant, Freund's incomplete adjuvant, KLH, monophosphoryl lipid A (MPL), alum, and saponins, including QS-21, imiquimod, R848, or combinations thereof.
- Toll-like receptors (TLRs) function as sensors of infection and induce the activation of innate and adaptive immune responses. TLRs recognize a wide variety of ligands, called pathogen-associated molecular patterns (PAMPs). Upon recognizing conserved pathogen-associated molecular products, TLRs activate host defense responses through their intracellular signaling domain, the Toll/interleukin-1 receptor (TIR) domain, and the downstream adaptor protein MyD88. Dendritic cells and macrophages normally respond to Toll-like receptor (TLR) ligands and cytokines (for example, interleukin-1β; IL-6 and tumor necrosis factor, TNF), which they also produce; natural killer (NK) cells and T cells are also involved in the pro-inflammatory circuit. After TLR stimulation by bacterial compounds, innate immune cells release a range of cytokines. Some examples of TLR ligands include, but are not limited to, lipoproteins; peptidoglycan, zymosan (TLR2), double-stranded RNA, polyI:polyC (TLR3), lipopolysaccharide, heat shock proteins, taxol Taxol® (TLR4), flagellin (TLR5), and imidazoquinolines-R848, resiquimod, imiquimod; ssRNA (TLR7/8), beta-lymphocytes (TLR10) and uropathogenic E. coli (TLR11).
- The methods according to this aspect of the invention are useful for model studies of the immune system. The methods are also useful for the prophylactic or therapeutic treatment of human or animal disease. For example, the methods are useful for pediatric and veterinary vaccine applications.
- In a fifth aspect, the invention provides methods for therapeutically treating a vertebrate having a disease or disorder, such methods comprising administering to the vertebrate an immunomer or immunomer conjugate according to the invention. In various embodiments, the disease or disorder to be treated is cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, allergy, asthma or a disease caused by a pathogen. Pathogens include bacteria, parasites, fungi, viruses, viroids and prions. Administration is carried out as described for the fourth aspect of the invention.
- For purposes of the invention, the term “allergy” includes, without limitation, food allergies atopic dermatitis, allergic rhinitis (also known as hay fever), allergic conjunctivitis, urticaria (also known as hives), respiratory allergies and allergic reactions to other substances such as latex, medications and insect stings or problems commonly resulting from allergic rhinitis-sinusitis, otitis media and COPD. The term “airway inflammation” includes, without limitation, asthma. Specific examples of asthma include, but are not limited to, allergic asthma, non-allergic asthma, exercised-induced asthma, occupational asthma, and nocturnal asthma.
- Allergic asthma is characterized by airway obstruction associated with allergies and triggered by substances called allergens. Triggers of allergic asthma include, but are not limited to, airborne pollens, molds, animal dander, house dust mites and cockroach droppings. Non-allergic asthma is caused by viral infections, certain medications or irritants found in the air, which aggravate the nose and airways. Triggers of non-allergic asthma include, but are not limited to, airborne particles (e.g., coal, chalk dust), air pollutants (e.g., tobacco smoke, wood smoke), strong odors or sprays (e.g., perfumes, household cleaners, cooking fumes, paints or varnishes), viral infections (e.g., colds, viral pneumonia, sinusitis, nasal polyps), aspirin-sensitivity, and gastroesophageal reflux disease (GERD). Exercise-induced asthma (EIA) is triggered by vigorous physical activity. Symptoms of EIA occur to varying degrees in a majority of asthma sufferers and are likely to be triggered as a result of breathing cold, dry air while exercising. Triggers of EIA include, but are not limited to, breathing airborne pollens during exercise, breathing air pollutants during exercise, exercising with viral respiratory tract infections and exercising in cold, dry air. Occupational asthma is directly related to inhaling irritants and other potentially harmful substances found in the workplace. Triggers of occupational asthma include, but are not limited to, fumes, chemicals, gases, resins, metals, dusts, vapors and insecticides.
- As used herein, the term “autoimmune disorder” refers to disorders in which “self” proteins undergo attack by the immune system. Such term includes autoimmune asthma.
- Without wishing to be bound to any particular theory, decreased exposure to bacteria may be partially responsible for the increased incidence of, severity of, and mortality due to allergic diseases such as asthma, atopic dermatitis, and rhinitis in the developed countries. This hypothesis is supported by evidence that bacterial infections or products can inhibit the development of allergic disorders in experimental animal models and clinical studies. Bacterial DNA or synthetic oligodeoxynucleotides containing unmethylated CpG dinucleotides and/or modified CpG dinucleotides in certain sequence contexts (CpG DNA) potently stimulate innate immune responses and thereby acquired immunity. The immune response to CpG DNA includes activation of innate immune cells, proliferation of B cells, induction of Th1 cytokine secretion, and production of immunoglobulins (Ig). The activation of immune cells by CpG DNA occurs via Toll-like receptor 9 (TLR9), a molecular pattern recognition receptor. CpG DNA induce strong Th1-dominant immune responses characterized by secretion of IL-12 and IFN-{tilde over (γ)}. Immunomers (IMO) alone or as allergen conjugates decrease production of IL-4, IL-5, and IgE and reduce eosinophilia in mouse models of allergic asthma. IMO compounds also effectively reverse established atopic eosinophilic airway disease by converting a Th2 response to a Th1 response.
- OVA with alum is commonly used to establish a Th2-dominant immune response in various mouse and rat models. The Th2 immune response includes increased IL-4, IL-5, and IL-13 production, elevated serum levels of total and antigen-specific IgE, IgG1, and lower levels of IgG2a. IMO compounds prevent and reverse established Th2-dominant immune responses in mice. The co-administration of IMO compounds with OVA/alum to mice reduces IL-4, IL-5, and IL-13 production and induces IFN-γ production in spleen-cell cultures subjected to antigen re-stimulation. Furthermore, IMO compounds inhibit antigen-specific and total IgE and enhance IgG2a production in these mice.
- Injection of OVA/alum and IMO compounds induces a lymphocyte antigen-recall response (Th1-type) in mice characterized by low levels of Th2-associated cytokines, IgE and IgG1, and high levels of Th1-associated cytokines and IgG2a. Co-administration of IMO compounds with other kinds of antigens, such as S. masoni egg and hen egg lysozyme, also result in reversal of the Th2-response to a Th1-dominant response in in vitro and in vivo studies. As described herein, IMO compounds effectively prevent development of a Th2 immune response and allow a strong Th1 response.
- While Th2 cytokines trigger an Ig isotype switch towards production of IgE and IgG1, the Th1 cytokine IFN-γ induces production of IgG2a by B-lymphocytes. Mice injected with OVA/alum and IMO compounds produce lower levels of IL-4, IL-5, and IL-13 and higher levels of IFN-γ, accompanied by lower IgE and IgG1 and higher IgG2a levels, than mice injected with OVA/alum alone. This suggests the existence of a close link between Th1-cytokine induction and immunoglobulin isotype switch in mice that receive antigen and IMO compounds.
- Serum antigen-specific and total IgE levels are significantly lower in mice receiving OVA/alum and IMO compounds than in mice receiving OVA/alum alone. In contrast, OVA-specific IgG1 levels are insignificantly changed and total IgG1 levels are only slightly decreased compared with mice injected with OVA/alum alone (data not shown). The different response may result from different mechanisms involved in the control of IgE and IgG1 class switch, though both isotypes are influenced by IL-4 and IL-13. For example, IL-6 promotes B lymphocytes to synthesize IgG1 in the presence of IL-4.
- In a sixth aspect the invention provides a method for preventing cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen in a vertebrate. This method comprises administering to the vertebrate any one of the compositions, alone or in combination, disclosed in the first, second and third aspects of the invention. Pathogens include bacteria, parasites, fungi, viruses, viroids and prions. Administration is carried out as described for the fourth aspect of the invention.
- In any of the methods according to the invention, the immunostimulatory oligonucleotide and/or immunomer or a conjugate thereof can be administered in combination with any other agent useful for treating the disease or condition that does not diminish the immunostimulatory effect of the oligonucleotide or immunomer. For purposes of this aspect of the invention, the term “in combination with” means in the course of treating the same disease in the same patient, and includes administering the oligonucleotide and/or immunomer and an agent in any order, including simultaneous administration, as well as any temporally spaced order, for example, from sequentially with one immediately following the other to up to several days apart. Such combination treatment may also include more than a single administration of the immunomer, and independently the agent. The administration of the oligonucleotide and/or immunomer and agent may be by the same or different routes.
- In any of the methods according to the invention, the agent useful for treating the disease or condition includes, but is not limited to, vaccines, antigens, antibodies, cytotoxic agents, allergens, antibiotics, antisense oligonucleotides, peptides, proteins, gene therapy vectors, DNA vaccines and/or adjuvants to enhance the specificity or magnitude of the immune response, or co-stimulatory molecules such as cytokines, chemokines, protein ligands, trans-activating factors, peptides and peptides comprising modified amino acids. Additionally, the agent can include DNA vectors encoding for antigen or allergen. In these embodiments, the immunomers of the invention can variously act as adjuvants and/or produce direct immunostimulatory effects.
- The examples below are intended to further illustrate certain preferred embodiments of the invention, and are not intended to limit the scope of the invention.
- CpG oligonucleotides (immunostimulatory oligonucleotides/immunomers) were synthesized on a 1 to 2 μmole scale using β-cyanoethylphosphoramidites on a PerSeptive Biosystem's 8909 Expedite DNA synthesizer (PerSeptive Biosystem, Boston, Mass.). The phosphoramidites of dA, dG, dC, and T were obtained from PE Biosystems (Foster City, Calif.). As described by Iyer R. P., et al. (J. Am. Chem. Soc. 112: 1253-1254 (1990)), an iodine oxidizing agent was used to obtain the phosphorothioate backbone modification. All oligos were deprotected using standard protocols, purified by HPLC, and dialyzed against USP quality sterile water for irrigation. The oligos were lyophilized and dissolved again in distilled water and the concentrations were determined from UV absorbance at 260 nm. All oligos were characterized by CGE and MALDI-TOF mass spectrometry (Applied Biosystem's Voyager-DETM STR Biospectrometry™ Workstation) for purity and molecular mass, respectively. The purity of full-length oligos ranged from 90-96% with the rest being shorter by one or two nucleotides (n−1 and n−2) as determined by CGE and/or denaturing PAGE. All oligos contained less than <0.1 EU/mL of endotoxin as determined by the Limulus assay (Bio-Whittaker now known as Cambrex Bio Science Walkersville, Inc., Walkersville, Md.).
- Thermal melting studies were carried out in 1 mL solution of 10 mM disodium hydrogen phosphate, pH 7.2±0.2, containing 150 mM NaCl, and 2 mM MgCl2. The solutions were heated to 95° C. for 10 min and allowed to come to room temperature slowly before being stored at 4° C. overnight. The final concentration of oligonucleotide strand was 2.0 μM. UV thermal melting measurements were performed at 260 nm on a Perkin-Elmer Lambda 20 Spectrophotometer attached to a peltier thermal controller and a personal computer using 1 cm path length quartz cuvettes at a heating rate of 0.5° C./min. Melting temperatures (Tm) were taken as the temperature of half-dissociation and were obtained from first derivative plots. Each Tm value is an average of two or three independent experiments and the values were within ±1.0° C.
- Spleen cells from 4-8 week old BALB/c, C57BL/6 or C3H/HeJ mice were cultured in RPMI complete medium as described by Zhao, Q., et al. (Biochem Pharmacol. 51: 173-182 (1996)) and Branda, R. F., et al. (Biochem. Pharmacol. 45: 2037-2043 (1993)). Murine J774 macrophages (American Type Culture Collection, University Boulevard, Manassas, Va. 20110-2209) were cultured in Dulbecco's modified Eagles medium supplemented with 10% (v/v) fetal calf serum and antibiotics (100 IU/mL of penicillin G/streptomycin). All other culture reagents were purchased from Mediatech (Gaithersburg, Md.).
- Typically, mouse (Balb-C) spleen cells were cultured with immunomer compounds at concentrations of 0.1, 1.0, and 10.0 μg/ml for 48 h and cell proliferation was determined by 3H-uridine incorporation, as described by Zhao, Q., et al. (Biochem Pharmacol. 51: 173-182 (1996)).
- Mouse spleen or J774 cells were plated in 24-well dishes using 5×106 or 1×106 cells/mL, respectively. The immunomer compounds dissolved in TE buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) were added to a final concentration of 0.03, 0.1, 0.3, 1.0, 3.0, or 10.0 μg/mL to the cell cultures. The cells were then incubated at 37° C. for 24 hr and the supernatants were collected for ELISA assays. The experiments were performed two or three times for each immunomer compound and in triplicate for each concentration. The secretion of IL-12 and IL-6 was measured by sandwich ELISA as described by Bhagat L., et al. (Biochem. Biophys. Res. Commun. 300: 853-861 (2003)). The required reagents, including cytokine antibodies and standards were purchased from BD Biosciences Pharmingen (San Diego, Calif.).
- Female BALB/c mice (4-6 weeks, 19-21 gm) were divided into groups of three mice. Immunomer compounds were dissolved in sterile phosphate buffered saline (PBS) and administered subcutaneously (SC) to mice at a dose of 5 mg/kg. The mice were sacrificed after 48 hr and the spleens were harvested and weighed as described by Zhao, Q., et al. (Biochem Pharmacol. 51: 173-182 (1996)) and Branda, R. F., et al. (Biochem. Pharmacol. 45: 2037-2043 (1993)).
- Toll-like receptor 9 (TLR9) has been shown to recognize unmethylated CpG-dinucleotides in bacterial, plasmid and synthetic DNAs (Hemmi H., et al. Nature 408: 740-745 (2000)) and activate stress kinase (Yi A. K., et al. J. Immunol. 161: 4493-4497 (1998)) and NF-κB pathways (Stacey K. J., et al. J. Immunol. 157: 2116-2122 (1996)). NF-κB activation in J774 cells treated with immunomer compounds was carried out and analyzed by EMSA as described Yu D., et al. (Biochem. Biophys. Res. Commun. 297: 83-90 (2002)) and Bhagat L., et al. (Biochem. Biophys. Res. Commun. 300: 853-861 (2003)).
- PBMCs from freshly drawn healthy volunteer blood (CBR Laboratories, Boston, Mass.) were isolated by Ficoll density gradient centrifugation method (Histopaque-1077, Sigma) and B cells were isolated from PBMCs by positive selection using the CD19 cell isolation kit (Miltenyi Biotec) according to the manufacturer's instructions. Table 1 shows the immunostimulatory activity of immunomer compounds of the invention in C57BL/6 Splenocyte Assay.
-
TABLE 1 Immunomer Structure and C57BL/6 Splenocyte Assay (24 hs) IL-12 IL-12 IL-12 (pg/ml) (pg/ml) (pg/ml) SEQ ID NO Sequences and Modification (5′-3′) 1 μg/ml 1 μg/ml 1 μg/ml 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 6396 ± 10 911 ± 61 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 7275 ± 77 749 ± 80 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 8034 ± 14 918 ± 136 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 752 ± 98 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 389 ± 59 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 717 ± 25 29 5′-CTGTCo G 2TTCTC-X-CTCTTG 2 oCTGTC-5′ 849 ± 29 30 5′-TCG,TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 75 ± 28 104 ± 7 IL-6 IL-6 IL-12 (pg/ml) (pg/ml) (pg/ml) SEQ ID NO Sequences and Modification (5′-3′) 1 μg/ml 1 μg/ml 1 μg/ml 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 2195 ± 77 423 ± 99 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 3278 ± 2 840 ± 243 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 7080 ± 0 1553 ± 670 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 693 ± 226 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 1329 ± 53 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 18 ± 3 29 5′-CTGTCo G 2TTCTC-X-CTCTTG 2 oCTGTC-5′ 1230 ± 83 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 102 ± 5 12 ± 2 Normal phase represents a phosphorothioate linkage; o represents a phosphodiester linkage. G 1 =2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker Y = C3 Linker - pDCs were isolated from human PBMCs using a BDCA-4 cell isolation kit (Miltenyi Biotec) according to the manufacturer's instructions. pDC were plated in 96-well plates using 1×106 cells/mL, 200 μL/well). The immunomer compounds were added to a final concentration of 0.3, 1.0, 3.0, or 10.0 μg/mL to the cell cultures and incubated at 37° C. for 24 hr. Supernatants were then harvested and assayed for IFN-α and IFN-β using ELISA kit (PBL). Tables 2A-2D show an average ±SD of IFN-α and IFN-β for immunomer compounds according to the invention at a concentration of 10.0 μg/mL.
-
TABLE 2A Immunomer Structure and Immunostimulatory Activity in Human DC Assay (24 hs) IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 26112 ± 604 25825 ± 416 96264 ± 605 2 5′-TCG 1AACG 1TTCG-X-GCTTG 1CAAG 1CT-5′ 20340 ± 106 12270 ± 306 105804 ± 688 3 5′-TCTCACCTTCT-X-TCTTCCACTCT-5′ 185 ± 0 311 ± 4 1649 ± 262 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 5 5′-TCG 2AACG 2TTCG-X-GCTTG 2CAAG 2CT-5′ media 177 ± 0 177 ± 0 0 ± 0 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 41718 ± 1015 25011 ± 5 19608 ± 5 2 5′-TCG 1AACG 1TTCG-X-GCTTG 1CAAG 1CT-5′ 49176 ± 302 14014 ± 1414 21988 ± 1413 3 5′-TCTCACCTTCT-X-TCTTCCACTCT-5′ 0 ± 0 197 ± 0 201 ± 0 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 5 5′-TCG 2AACG 2TTCG-X-GCTTG 2CAAG 2CT-5′ media 0 ± 0 201 ± 0 196 ± 0 Normal phase represents a phosphorothioate linkage G1 = 2′-deoxy-7-deazaguanosine G2 = Arabinoguanosine X = Glycerol linker -
TABLE 2B Immunomer Structure and Immunostimulatory Activity in Human DC Assay (24 hs) IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 6 5′-TCG 1TCG 1AACG 1TTCG 1AGATGAT-3′ 37116 ± 1108 44624 ± 321 58908 ± 707 7 5′-TCG 2TCG 2AACG 2TTCG 2AGATGAT-3 6606 ± 950 5022 ± 334 15637 ± 698 8 5′-TCG 3TCG 3AACG 3TTCG 3AGATGAT-3′ 1405 ± 121 7750 ± 618 46311 ± 506 9 5′-TC 1GTC 1GAAC 1GTTC 1GAGATGAT-3′ 611 ± 33 231 ± 4 0 ± 0 10 5′-TC 2GTC 2GAAC 2GTTC 2GAGATGAT-3′ 269 ± 7 185 ± 0 2574 ± 64 11 5′-TC 3GTC 3GAAC 3GTTC 3GAGATGAT-3 191 ± 0 188 ± 0 0 ± 0 media 177 ± 0 177 ± 0 0 ± 0 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 6 5′-TCG 1TCG 1AACG 1TTCG 1AGATGAT-3′ 98178 ± 375 68722 ± 1358 31678 ± 715 7 5′-TCG 2TCG 2AACG 2TTCG 2AGATGAT-3′ 40782 ± 885 19180 ± 735 8696 ± 1122 8 5′-TCG 3TCG 3AACG 3TTCG 3AGATGAT-3′ 12446 ± 894 42195 ± 2665 582 ± 78 9 5′-TC 1GTC 1GAAC 1GTTC 1GAGATGAT-3′ 10175 ± 206 15966 ± 1256 6857 ± 1335 10 5′-TC 2GTC 2GAAC 2GTTC 2GAGATGAT-3′ 13028 ± 911 1947 ± 204 30 ± 5 11 5′-TC 3GTC 3GAAC 3GTTC 3GAGATGAT-3′ 0 ± 0 355 ± 16 17 ± 0 media 0 ± 0 12 ± 0 10 ± 0 Normal phase represents a phosphorothioate linkage G1 = 2′-deoxy-7-deazaguanosine G2 = Arabinoguanosine G3 = 2′-deoxyinosine C1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine C2 = Arabinocytidine C3 = 2′-deoxy-5-hydroxycytidine -
TABLE 2C Immunomer Structure and Immunostimulatory Activity in Human DC Assay (24 hs) IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 67088 ± 306 35055 ± 659 62805 ± 328 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 12588 ± 448 19986 ± 1418 38002 ± 1087 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 16090 ± 179 16712 ± 584 90560 ± 1690 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 9092 ± 291 9286 ± 615 60570 ± 867 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 770 ± 158 208 ± 28 5529 ± 286 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 40353 ± 542 33164 ± 419 72730 ± 954 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC1 GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 160 ± 7 259 ± 20 0 ± 0 INF-α INF-α INF-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 66980 ± 217 6552 ± 1 7992 ± 24 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 83115 ± 134 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 61230 ± 1120 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG1 CTTG 1CT-5′ 34430 ± 451 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 2044 ± 62 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 33716 ± 872 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 2440 ± 23 2403 ± 4 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 1316 ± 0 1683 ± 10 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 546 ± 0 0 ± 0 0 ± 0 INF-α INF-α INF-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 31227 ± 1341 9777 ± 10 10008 ± 10 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 6083 ± 184 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 2164 ± 4 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 0 ± 0 0 ± 0 0 ± 0 IFN-β IFN-β (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN8 DN9 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5 1370 ± 54 650 ± 38 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG1 CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 0 ± 0 0 ± 0 Normal phase represents a phosphorothioate linkage G 1 = 2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker -
TABLE D Immunomer Structure and Immunostimulatory Activity in Human DC Assay (24 hs) IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 3145 ± 4 5808 ± 28 22050 ± 407 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 4710 ± 31 5656 ± 0 14157 ± 10 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 228 ± 0 234 ± 0 116 ± 0 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 16100 ± 542 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 23768 ± 137 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 5824 ± 530 2090 ± 81 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 9582 ± 49 1623 ± 108 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 6912 ± 157 1577 ± 168 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 19570 ± 467 2254 ± 25 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCo G 2TTCTC-X-CTCTTG 2 oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTrCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 125 ± 3 157 ± 0 179 ± 0 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 1049 ± 13 15594 ± 48 6024 ± 135 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 2230 ± 78 6118 ± 3′10 3162 ± 189 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 1535 ± 130 6680 ± 35 1558 ± 45 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 16053 ± 3815 9502 ± 57 6228 ± 0 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 6632 ± 184 3166 ± 242 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 6864 ± 394 1146 ± 42 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 157 ± 0 82 ± 0 94 ± 2 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN10 DN11 DN12 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 8154 ± 597 31854 ± 136 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 6413 ± 876 14493 ± 613 9642 ± 129 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 2688 ± 293 4486 ± 94 24 and 37 5′-TCG 1AACGTTCG 1-Y-TCTTCCACTCT-5′ 7214 ± 18 10068 ± 31 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 11474 ± 402 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 375 ± 23 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 5508 ± 410 13956 ± 355 6009 ± 240 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 5599 ± 146 11824 ± 720 9977 ± 1379 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 11946 ± 159 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 0 ± 0 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 10032 ± 9 33 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ 6420 ± 139 Media 80 ± 0 101 ± 7 0 ± 0 Normal phase represents a phosphorothioate linkage; o represents a phosphodiester linkage. G 1 = 2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker Y = C3 Linker - The secretion of IFN-α in vertebrate cells, preferably BALB/c mouse spleen cells or human PBMC, was measured by sandwich ELISA. The required reagents including cytokine antibodies and cytokine standards were purchased form PharMingen, San Diego, Calif. ELISA plates (Costar) were incubated with appropriate antibodies at 5 μg/mL in PBSN buffer (PBS/0.05% sodium azide, pH 9.6) overnight at 4° C. and then blocked with PBS/1% BSA at 37° C. for 30 minutes. Cell culture supernatants and cytokine standards were appropriately diluted with PBS/10% FBS, added to the plates in triplicate, and incubated at 25° C. for 2 hours. Plates were overlaid with 1 μg/mL appropriate biotinylated antibody and incubated at 25° C. for 1.5 hours. The plates were then washed extensively with PBS-T Buffer (PBS/0.05% Tween 20) and further incubated at 25° C. for 1.5 hours after adding streptavidin conjugated peroxidase (Sigma, St. Louis, Mo.). The plates were developed with Sure Blue™ (Kirkegaard and Perry) chromogenic reagent and the reaction was terminated by adding Stop Solution (Kirkegaard and Perry). The color change was measured on a Ceres 900 HDI Spectrophotometer (Bio-Tek Instruments).
- Human peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood of healthy volunteers by Ficoll-Paque density gradient centrifugation (Histopaque-1077, Sigma, St. Louis, Mo.). Briefly, heparinized blood was layered onto the Histopaque-1077 (equal volume) in a conical centrifuge and centrifuged at 400×g for 30 minutes at room temperature. The buffy coat, containing the mononuclear cells, was removed carefully and washed twice with isotonic phosphate buffered saline (PBS) by centrifugation at 250×g for 10 minutes. The resulting cell pellet was then resuspended in RPMI 1640 medium containing L-glutamine (MediaTech, Inc., Herndon, Va.) and supplemented with 10% heat inactivated FCS and penicillin-streptomycin (100 U/ml). Cells were cultured in 24 well plates for different time periods at 1×106 cells/ml/well in the presence or absence of oligonucleotides. At the end of the incubation period, supernatants were harvested and stored frozen at −70° C. until assayed for various cytokines including IFN-α (BioSource International) by sandwich ELISA. The results are shown in Table 3A-3D below.
- In all instances, the levels of IFN-α in the cell culture supernatants was calculated from the standard curve constructed under the same experimental conditions for IFN-α.
-
TABLE 3A Immunomer Structure and Immunostimulatory Activity in Human PBMC Assay (24 hs) INF-α INF-α INF-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 8222 ± 44 6114 ± 1 3604 ± 1 2 5′-TCG 1AACG 1TTCG-X-GCTTG 1CAAG 1CT-5′ 6700 ± 7 6272 ± 24 2822 ± 24 3 5′-TCTCACCTTCT-X-TCTTCCACTCT-5′ 0 ± 0 80 ± 0 80 ± 0 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 5 5′-TCG 2AACG 2TTCG-X-GCTTG 2CAAG 2CT-5 media 0 ± 0 78 ± 0 83 ± 0 INF-α INF-α INF-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 7038 ± 11 2921 ± 321 12514 ± 351 2 5′-TCG 1AACG 1TTCG-X-GCTTG 1CAAG 1CT-5′ 7332 ± 269 3647 ± 704 10872 ± 613 3 5′-TCTCACCTTCT-X-TCTTCCACTCT-5′ 19 ± 7 0 ± 0 0 ± 0 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 5 5′-TCG 2AACG 2TTCG-X-GCTTG 2CAAG 2CT-5′ media 33 ± 0 0 ± 0 0 ± 0 Normal phase represents a phosphorothioate linkage G1 = 2′-deoxy-7-deazaguanosine G2 = Arabinoguanosine X = Glycerol linker -
TABLE 3B Immunomer Structure and Immunostimulatory Activity in Human PBMC Assay (24 hs) IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 82 g/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 6 5′-TCG 1TCG 1AACG 1TTCG 1AGATGAT-3′ 3487 ± 1015 268 ± 3′10 3883 ± 50 7 5′-TCG 2TCG 2AACG 2TTCG 2AGATGAT-3′ 9 ± 0 30 ± 0 0 ± 0 8 5′-TCG 3TCG 3AACG 3TTCG 3AGATGAT-3′ 126 ± 1 0 ± 0 0 ± 0 9 5′-TC 1GTC 1GAAC 1GTTC 1GAGATGAT-3′ 0 ± 0 0 ± 0 0 ± 0 10 5′-TC 2GTC 2GAAC 2GTTC 2GAGATGAT-3′ 0 ± 0 20 ± 0 0 ± 0 11 5′-TC 3GTC 3GAAC 3GTTC 3GAGATGAT-3′ 11 ± 1 5 ± 0 76 ± 0 media 33 ± 0 0 ± 0 0 ± 0 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 82 g/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 6 5′-TCG 1TCG 1AACG 1TTCG 1AGATGAT-3′ 1950 ± 88 4342 ± 225 426 ± 85 7 5′-TCG 2TCG 2AACG 2TTCG 2AGATGAT-3′ 0 ± 0 1807 ± 0 31 ± 15 8 5′-TCG 3TCG 3AACG 3TTCG 3AGATGAT-3′ 0 ± 0 2876 ± 344 48 ± 5 9 5′-TC 1GTC 1GAAC 1GTTC 1GAGATGAT-3 0 ± 0 5 ± 0 4 ± 0 10 5′-TC 2GTC 2GAAC 2GTTC 2GAGATGAT-3′ 0 ± 0 8 ± 0 5 ± 3 11 5′-TC 3GTC 3GAAC 3GTTC 3GAGATGAT-3′ 0 ± 0 2111 ± 330 11 ± 3′10 media 0 ± 0 48 ± 9 11 ± 2 Normal phase represents a phosphorothioate linkage G1 = 2′-deoxy-7-deazaguanosine G2 = Arabinoguanosine G3 = 2′-deoxyinosine C1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine C2 = Arabinocytidine C3 = 2′-deoxy-5-hydroxycytidine -
TABLE 3C Immunomer Structure and Immunostimulatory Activity in Human PBMC Assay (24 hs) IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3′ 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 208 ± 33 432 ± 5 1345 ± 20 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 11 ± 1 59 ± 0 173 ± 41 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 16 ± 1 55 ± 7 324 ± 49 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 882 ± 32 733 ± 80 2035 ± 16 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 50 ± 27 39 ± 17 4 ± 0 15 5′-TCGlTTGlCAACG 1-X-G 1CAACG 1TTG 1CT-5′ 604 ± 6 465 ± 70 1902 ± 30 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5 media 20 ± 4 12 ± 0 3 ± 0 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 900 ± 8 432 ± 26 582 ± 20 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 9 ± 26 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 441 ± 76 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 732 ± 8 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 19 ± 5 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 880 ± 8 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 27 ± 0 26 ± 0 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 19 ± 0 23 ± 0 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 6 ± 1 0 ± 0 0 ± 0 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 1 5′-TCG 1AACG 1TTCG 1-X-GCTTG 1CAAG 1CT-5′ 324 ± 18 578 ± 28 741 ± 25 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 6 ± 0 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 0 ± 0 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 0 ± 0 0 ± 0 0 ± 0 Normal phase represents a phosphorothioate linkage G 1 = 2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker -
TABLE 3D Immunomer Structure and Immunostimulatory Activity in Human PBMC Assay (24 hs) IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 8 ± 0 65 ± 3 314 ± 23 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 9 ± 0 10 ± 2 487 ± 87 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TC 1TCCACTCT-5′ 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TC 1TCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 11 ± 0 10 ± 0 0 ± 0 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 1446 ± 7 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 942 ± 1 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 126 ± 2 159 ± 13 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 239 ± 23 356 ± 109 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5 147 ± 23 185 ± 46 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 107 ± 15 148 ± 37 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 0 ± 0 68 ± 5 67 ± 0 IL-10 IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 242 ± 1 549 ± 37 9 ± 0 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTrG 2CTGTCT-5′ 241 ± 2 250 ± 12 14 ± 1 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 238 ± 0 224 ± 25 8 ± 1 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 238 ± 0 668 ± 10 41 ± 7 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 223 ± 31 12 ± 0 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 47 ± 4 5 ± 1 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 0 ± 0 0 ± 0 2 ± 0 IFN-α IFN-α IFN-α (pg/ml) (pg/ml) (pg/ml) 10 μg/ml 10 μg/ml 10 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN10 DN11 DN12 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 232 ± 8 252 ± 16 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 67 ± 1 195 ± 3′10 364 ± 8 23 and 36 5′-TCG 1AACGTTCG 1-Y-TCTTGC 1TGTCT-5′ 70 ± 1 148 ± 3′10 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 443 ± 29 678 ± 133 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 298 ± 16 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 12 ± 1 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 2 ± 0 94 ± 5 512 ± 33 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 3 ± 0 61 ± 18 168 ± 25 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 992 ± 2 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 9 ± 0 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 1528 ± 20 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ 69 ± 10 Media 0 ± 0 6 ± 0 7 ± 0 Normal phase represents a phosphorothioate linkage; o represents a phosphodiester linkage. G 1 = 2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker Y = C3 Linker - Cell surface markers of CD69 and CD86 were detected with a Coulter Epics-XL Flow Cytometer using anti-human CD69-Fitc and CD86-Fitc, which were purchased from BD Pharmingen (San Diego, USA). Staining methods were briefly descried as follow. The activated culture cells were blocked with 10% Human AB serum (Sigma) in staining buffer (PBS with 1% BSA and 0.1% NaN3) at 4° C. for 1 hour and stained with the antibodies at 4° C. overnight. PBMCs (4×105) were stained with CD69-Fitc and CD86-Fitc. PDCs (2×105) were stained CD86-Fitc. The cell staining data were acquired and analyzed with Coulter System II software (see Tables 4A-4F below).
-
TABLE 4A Immunomer Structure and Expression of BC from Human PBMC (2 × 106 cell/ml) (24 hs) % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 36.4 17.7 36.4 2 5′-TCG 1AACG 1TTCG-X-GCTTG 1CAAG 1CT-5′ 27.2 6.3 30.4 3 5′-TCTCACCTTCT-X-TCTTCCACTCT-5′ 15 7.3 11.3 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 5 5′-TCG 2AACG 2TTCG-X-GC 1TG 2CAAG 2CT-5′ media 10.7 8 7.6 % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 33.3 12.9 27.6 2 5′-TCG 1AACG 1TTCG-X-GCTTG 1CAAG 1CT-5′ 25 17.5 32.4 3 5′-TCTCACCTTCT-X-TCTTCCACTCT-5′ 10 21.3 17.6 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 5 5′-TCG 2AACG 2TTCG-X-GC 1TG 2CAAG 2CT-5′ media 5.2 5.4 11.8 % CD69 % CD69 % CD69 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 27.5 61 75.8 2 5′-TCG 1AACG 1TTCG-X-GCTTG 1CAAG 1CT-5′ 52.5 46.5 69.7 3 5′-TCTCACCTTCT-X-TCTTCCACTCT-5′ 0 11.8 8.5 4 5-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 5 5′-TCG 2AACG 2TTCG-X-GCTTG 2CAAG 2CT-5′ media 0 11.1 11.1 % CD69 % CD69 % CD69 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 58.3 51.8 39.1 2 5′-TCG 1AACG 1TTCG-X-GCTTG 1CAAG 1CT-5′ 62.5 56.5 43.6 3 5′-TCTCACCTTCT-X-TCTTCCACTCT-5′ 0 31.1 16.9 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 5 5′-TCG 2AACG 2TTCG-X-GCTTG 2CAAG 2CT-5′ media 5.2 18.9 8.9 Normal phase represents a phosphorothioate linkage G1 = 2′-deoxy-7-deazaguanosine G2 = Arabinoguanosine X = Glycerol linker -
TABLE 4B Immunomer Structure and Expression of BC from Human PBMC (2 × 106 cell/ml) (24 hs) % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 6 5′-TCG 1TCG 1AACG 1TTCG 1AGATGAT-3′ 43.4 25 34.6 7 5′-TCG 2TCG 2AACG 2TTCG 2AGATGAT-3′ 46.7 42.6 47.6 8 5′-TCG 3TCG 3AACG 3TTCG 3AGATGAT-3′ 41.1 25.7 38.5 9 5′-TC 1GTC 1GAAC 1GTTC 1GAGATGAT-3′ 25 20.8 27.6 10 5′-TC 2GTC 2GAAC 2GTTC 2GAGATGAT-3′ 36.4 22.2 26 11 5′-TC 3GTC 3GAAC 3GTTC 3GAGATGAT-3′ 30 17 22.2 media 10.7 8 7.6 % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 6 5′-TCG 1TCG 1AACG 1TTCG 1AGATGAT-3′ 40 43.5 24.8 7 5′-TCG 2TCG 2AACG 2TTCG 2AGATGAT-3′ 36.4 41 36.2 8 5′-TCG 3TCG 3AACG 3TTCG 3AGATGAT-3′ 57.1 30.4 34.9 9 5′-TC 1GTC 1GAAC 1GTTC 1GAGATGAT-3′ 13.3 12.1 15.2 10 5′-TC 2GTC 2GAAC 2GTTC 2GAGATGAT-3′ 25 14.4 16.3 11 5′-TC 3GTC 3GAAC 3GTTC 3GAGATGAT-3′ 18.1 15 16.8 media 5.2 3.9 6.8 % CD69 % CD69 % CD69 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 6 5′-TCG 1TCG 1AACG 1TTCG 1AGATGAT-3′ 56.4 43.8 68.7 7 5′-TCG 2TCG 2AACG 2TTCG 2AGATGAT-3′ 55.6 58.6 65.5 8 5′-TCG 3TCG 3AACG 3TTCG 3AGATGAT-3 50 39.3 73.1 9 5′-TC 1GTC 1GAAC 1GTTC 1GAGATGAT-3′ 15.4 27 20 10 5′-TC 2GTC 2GAAC 2GTTC 2GAGATGAT-3′ 20 31.4 31.5 11 5′-TC 3GTC 3GAAC 3GTTC 3GAGATGAT-3′ 10 22.2 24.3 media 0 11.1 11.1 % CD69 % CD69 % CD69 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 6 5′-TCG 1TCG 1AACG 1TTCG 1AGATGAT-3′ 57.1 7 5′-TCG 2TCG 2AACG 2TTCG 2AGATGAT-3′ 60 8 5′-TCG 3TCG 3AACG 3TTCG 3AGATGAT-3′ 37.5 9 5′-TC 1GTC 1GAAC 1GTTC 1GAGATGAT-3′ 15.4 10 5′-TC 2GTC 2GAAC 2GTTC 2GAGATGAT-3′ 11.1 11 5′-TC 3GTC 3GAAC 3GTTC 3GAGATGAT-3′14.3 media 5.2 Normal phase represents a phosphorothioate linkage G1 = 2′-deoxy-7-deazaguanosine G2 = Arabinoguanosine G3 = 2′-deoxyinosine C1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine C2 = Arabinocytidine C3 = 2′-deoxy-5-hydroxycytidine -
TABLE 4C Immunomer Structure and Expression of BC from Human PBMC (2 × 106 cell/ml) (24 hs) % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 32.3 34.8 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 41.4 51.6 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 33.3 51.5 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 20 25.6 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 31.1 26.1 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 17.1 23.9 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 19.4 20.9 % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 15.4 33.3 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 30.7 45.4 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 30 41.6 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 8.6 2.7 % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 35.5 23.5 17.6 40 5-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 56.5 16 5-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 46.7 17 5-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 9 20 15.3 % CD69 % CD69 % CD69 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 23.5 64 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 20.8 62.5 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 13.6 59 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 12.5 46.4 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15.9 52.9 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 12.2 51.6 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 14.8 34 % CD69 % CD69 % CD69 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 53.8 62.5 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 12 5-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 4 5′-TCG 2AACGTTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 77.7 70.6 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 57.1 64.7 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 26.3 15 % CD69 % CD69 % CD69 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 28.6 50 25 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15 5-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 70.6 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 72.7 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 14.1 13.2 12 Normal phase represents a phosphorothioate linkage G 1 = 2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker -
TABLE 4D Immunomer Structure and Expression of BC from Human PBMC (2 × 106 cell/ml) (24 hs) % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 64.3 57.2 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 59.2 58.3 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 49.3 40.9 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 25.3 24.7 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15.4 17.2 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 30.6 23.7 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 2.6 13.9 % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 35.9 30.3 35.6 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 57.9 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 34.9 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 12.3 11.1 14 % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 1 5′-TCG 1AACG 1TTCG 1-X-G 1CTTG 1CAAG 1CT-5′ 28 32.3 40 5′-TCG 1AACG 1TTCT-X-TCTTG 1CAAG 1CT-5′ 12 5′-TCG 1AACG 1TTC-X-CTTG 1CAAG 1CT-5′ 13 5′-TCG 1TTCG 1AACG 1-X-G 1CAAG 1CTTG 1CT-5′ 14 5′-TCCAACCTTCG-X-GCTTCCAACCT-5′ 15 5′-TCG 1TTG 1CAACG 1-X-G 1CAACG 1TTG 1CT-5′ 4 5′-TCG 2AACG 2TTCG 2-X-G 2CTTG 2CAAG 2CT-5′ 16 5′-TCG 2AACG 2TTCT-X-TCTTG 2CAAG 2CT-5′ 17 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 18 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ media 10.9 12.6 Normal phase represents a phosphorothioate linkage G 1 = 2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker -
TABLE 4E Immunomer Structure and Expression of BC from Human PBMC assay (24 hs) % CD86 % CD86 % CD86 SEQ 1 μg/ml 1 μg/ml 1 μg/ml ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 9 34.6 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21.7 12.5 31.4 21 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ and 34 22 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ and 35 23 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ and 36 24 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ and 37 25 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ and 34 26 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ and 37 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1 T-5′ 32 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ and 38 33 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ and 39 Media 8.7 % CD86 % CD86 % CD86 SEQ 1 μg/ml 1 μg/ml 1 μg/ml ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 42.3 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 72.7 21 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 14.5 17.1 and 34 22 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 27.8 28.6 and 35 23 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 28.9 22.2 and 36 24 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 23.2 21.8 and 37 25 5′-TG 1CAAG 1CTTG1C-Y-TCTTG 1CTGTCT-5′ and 34 26 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ and 37 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ and 38 33 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ and 39 Media 5.9 4.0 6.0 % CD86 % CD86 % CD86 SEQ 1 μg/ml 1 μg/ml 1 μg/l ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 65 46.3 40.3 and 34 22 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 75 49.2 46.5 and 35 23 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 78.9 54.3 45 and 36 24 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 83.3 33.8 29.4 and 37 25 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ and 34 26 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ and 37 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 22.5 35.6 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 43.1 47.8 30 5′-TCG 1TGTCGTTT-X-TTTG 1CTGTG 1CT-5′ 31 5′TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ and 38 33 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ and 39 Media 4.6 0 10.5 % CD86 % CD86 % CD86 SEQ 1 μg/ml 1 μg/ml 1 μg/ml ID NO Sequences and Modification (5′-3′) DN10 DN11 DN12 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 24.4 60.7 and 34 22 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 23.9 61.5 53.8 and 35 23 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 32.8 72 and 36 24 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 22.7 52.6 and 37 25 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 31.7 and 34 26 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 23.9 and 37 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 21 57.1 29.6 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 34.7 63.1 43.5 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 24.5 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 28.6 32 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 44.2 and 38 33 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ 28.3 and 39 Media 19 8.6 18 % CD69 % CD69 % CD69 SEQ 1 μg/ml 1 μg/ml 1 μg/ml ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 13 22.2 19.2 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 52 30.7 59.3 21 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ and 34 22 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ and 35 23 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ and 36 24 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ and 37 25 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ and 34 26 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ and 37 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ and 38 33 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ and 39 Media 3 % CD69 % CD69 % CD69 SEQ 1 μg/ml 1 μg/ml 1 μg/ml ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 76 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 85.1 21 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 35 20 and 34 22 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 57.3 39.4 and 35 23 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 60.4 54.2 and 36 24 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 69 30.2 and 37 25 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ and 34 26 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ and 37 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ and 38 33 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ and 39 Media 10 5.9 10.1 % CD69 % CD69 % CD69 SEQ 1 μg/ml 1 μg/ml 1 μg/ml ID NO Sequences and Modification (5-3′) DN7 DN8 DN9 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 88.2 47.7 59.7 and 34 22 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 97 55 63.3 and 35 23 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 96.8 68.3 60.2 and 36 24 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 91.9 40.3 41.9 and 37 25 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ and 34 26 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ and 37 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 36 51.2 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 51.6 66.7 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 5′-TCG 1AACG 1TTCG 1-Y-GACA G 1CTGTCT-5′ and 38 33 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ and 39 Media 9 10.3 11.1 % CD69 % CD69 % CD69 SEQ 1 μg/ml 1 μg/ml 1 μg/ml ID NO Sequences and Modification (5′-3′) DN10 DN11 DN12 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 24 61.7 and 34 22 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 29.2 71.4 58 and 35 23 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 35.7 60.5 and 36 24 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 32.2 62.9 and 37 25 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 23.6 and 34 26 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 16.7 and 37 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 22.1 50 42.5 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 31.5 70.5 54.4 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 19.5 31 5′-TGhd 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 15.5 32 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 40 and 38 33 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ 19.3 and 39 Media 13.4 13.4 12.9 Normal phase represents a phosphorothioate linkage; o represents a phosphodiester linkage. G 1 = 2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker Y = C3 Linker -
TABLE 4F Immunomer Structure and Expression of DC from Human PBMC assay (24 hs) % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN1 DN2 DN3 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 11.9 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 12.5 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 13.7 % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 54.7 68 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 58.8 75.3 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 60.3 73.4 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 51.8 61.1 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 33.7 62.8 % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 45.4 88.7 78.3 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 54.9 89.3 79.1 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 55.3 88.6 79.9 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 47 85.7 n/a 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 82.1 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 89 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 47.5 56.1 53.2 % CD86 % CD86 % CD86 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN10 DN11 DN12 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 72 86.3 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 74.4 88.1 81.8 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 77.1 87.5 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 68.3 83.8 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 60.4 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 37.4 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 61.1 79.6 58.2 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 68.2 87.3 69.5 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 60.3 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 44.7 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 65.8 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ 49.1 Media 69.6 58.3 35.8 Normal phase represents a phosphorothioate linkage; o represents a phosphodiester linkage. G 1 = 2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker; Y = C3 Linker - A total of 1×105 B cells/200 μl were stimulated with 0.3, 1.0, 3.0, or 10.0 μg/mL concentrations of immunomer compounds of the invention for 16 hr, then pulsed with 0.75 μCi of [3H]-thymidine and harvested 8 h later. The incorporation of radioactivity was measured using liquid scintillation counter. Table 5 shows an average ±SD of B cell proliferation at a final concentration of 1.0 μg/mL.
-
TABLE 5 Immunomer Structure and Immunostimulatory Activity in Human B-Cell Proliferation Assay (24 hs) [3H]T [3H]T [3H]T (cpm) (cpm) (cpm) 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN4 DN5 DN6 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 20 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 21 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 31127 ± 6800 17626 ± 2809 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 33368 ± 1364 17131 ± 1366 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 30845 ± 2514 13826 ± 2331 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 34077 ± 3636 8073 ± 583 25 and 34 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 28 5′-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 29 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 30 5′-TCG 1TGTCG 1TTT-X-TTTG 1CTGTG 1CT-5′ 31 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 32 and 38 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 33 and 39 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 646 ± 236 457 ± 121 [3H]T [3H]T [3H]T (cpm) (cpm) (cpm) 1 μg/ml 1 μg/ml 1 μg/ml SEQ ID NO Sequences and Modification (5′-3′) DN7 DN8 DN9 19 5′-TCG 1AACG 2TTCG 1-X-G 1CTTG 2CAAG 1CT-5′ 21 and 34 5′-TCG 1AAC 1GTTCG 1-X-G 1CTTGC 1AAG 1CT-5′ 22 and 35 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 1CTGTCT-5′ 37731 ± 2901 23 and 36 5′-TCG 1AACG 1TTCG 1-Y-TCTTG 2CTGTCT-5′ 38405 ± 8056 24 and 37 5′-TCG 1AACG 1TTCG 1-Y-TCTTGC 1TGTCT-5′ 34702 ± 6196 25 and 34 5′-TCG 1AACG 1TTCG 1-Y-TCTTCCACTCT-5′ 23030 ± 1941 26 and 37 5′-TG 1CAAG 1CTTG 1C-Y-TCTTG 1CTGTCT-5′ 27 5′-TG 1CAAG 1CTTG 1C-Y-TCTTCCACTCT-5′ 28 5′-TG 1CAAG 1CTTG 1C-X-CG 1TTCG 1AACG 1T-5′ 29 5-CTGTCG 2TTCTCo-X-oCTCTTG 2CTGTC-5′ 30 5′-CTGTCoG 2TTCTC-X-CTCTTG 2oCTGTC-5′ 31 5′-TCG 1TGTCG 1T1T-X-TTTG 1CTGTG 1CT-5′ 32 and 38 5′-TG 1CTGTG 1CTTT-X-TTTCG 1TGTCG 1T-5′ 33 and 39 5′-TCG 1AACG 1TTCG 1-Y-GACAG 1CTGTCT-5′ 21 and 34 5′-TG 1CAACG 1CTTG 1C-Y-GACACG 1TGTCT-5′ Media 658 ± 205 Normal phase represents a phosphorothioate linkage; o represents a phosphodiester linkage. G 1 = 2′-deoxy-7-deazaguanosine G 2 = Arabinoguanosine C 1 = 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine X = Glycerol Linker Y = C3 Linker - While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.
Claims (9)
1.-13. (canceled)
14. A method for therapeutically treating a vertebrate having cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen, such method comprising administering to the patient an immunostimulatory oligonucleotide having the structure 5′-TCG1AACG1TTCG1-X-G1CTTG1CAAG1CT-5′,5′-CTGTCoG2TTCTC-X-CTCTTG2oCTGTC-5′,5′-CTGTCG2TTCTCo-X-oCTCTTG2CTGTC-5′,5′-TCG1AACG1TTCG1-X-TCTTG2CTGTCT-5′,5′-TCG1AACG1TTCG1-Y-GACAG1CTGTCT-5′; wherein X is a glycerol linker, Y is a C3-linker, G1 is 2′-deoxy-7-deazaguanosine, G2 is arabinoguanosine and o is phosphodiester linkage.
15. The method according to claim 14 , wherein the route of administration is selected from parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash.
16. A method for preventing cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma or a disease caused by a pathogen in a vertebrate, such method comprising administering to the vertebrate an immunostimulatory oligonucleotide having the structure 5′-TCG1AACG1TTCG1-X-G1CTTG1CAAG1CT-5′,5′-CTGTCoG2TTCTC-X-CTCTTG2oCTGTC-5′,5′-CTGTCG2TTCTCo-X-oCTCTTG2CTGTC-5′,5′-TCG1AACG1TTCG1-X-TCTTG2CTGTCT-5′,5′-TCG1AACG1TTCG1-Y-GACAG1CTGTCT-5′; wherein X is a glycerol linker, Y is a C3-linker, G1 is 2′-deoxy-7-deazaguanosine, G2 is arabinoguanosine and o is phosphodiester linkage.
17. The method according to claim 16 , wherein the route of administration is selected from parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop and mouthwash.
18. The method according to claim 14 , further comprising administering an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.
19. The method according to claim 16 , further comprising administering an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.
20. A pharmaceutical composition comprising an immunostimulatory oligonucleotide having the structure 5′-TCG1AACG1TTCG1-X-G1CTTG1CAAG1CT-5′,5′-CTGTCoG2TTCTC-X-CTCTTG2oCTGTC-5′,5′-CTGTCG2TTCTCo-X-oCTCTTG2CTGTC-5′,5′-TCG1AACG1TTCG1-X-TCTTG2CTGTCT-5′,5′-TCG1AACG1TTCG1-Y-GACAG1CTGTCT-5′; wherein X is a glycerol linker, Y is a C3-linker, G1 is 2′-deoxy-7-deazaguanosine, G2 is arabinoguanosine and o is phosphodiester linkage, and a physiologically acceptable carrier.
21. The pharmaceutical composition according to claim 20 , further comprising an antibody, antisense oligonucleotide, protein, antigen, allergen, chemotherapeutic agent or adjuvant.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/876,913 US20080193437A1 (en) | 2004-06-15 | 2007-10-23 | Immunostimulatory oligonucleotide multimers |
US12/565,151 US8420615B2 (en) | 2004-06-15 | 2009-09-23 | Immunostimulatory oligonucleotide multimers |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57998504P | 2004-06-15 | 2004-06-15 | |
US10/892,550 US20060074040A1 (en) | 2003-07-15 | 2004-07-15 | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
US59936204P | 2004-08-06 | 2004-08-06 | |
US11/153,054 US20060014713A1 (en) | 2004-06-15 | 2005-06-15 | Immunostimulatory oligonucleotide multimers |
US11/876,913 US20080193437A1 (en) | 2004-06-15 | 2007-10-23 | Immunostimulatory oligonucleotide multimers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/892,550 Continuation-In-Part US20060074040A1 (en) | 2003-07-15 | 2004-07-15 | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/565,151 Continuation US8420615B2 (en) | 2004-06-15 | 2009-09-23 | Immunostimulatory oligonucleotide multimers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080193437A1 true US20080193437A1 (en) | 2008-08-14 |
Family
ID=35600219
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/153,054 Abandoned US20060014713A1 (en) | 2004-06-15 | 2005-06-15 | Immunostimulatory oligonucleotide multimers |
US11/234,396 Expired - Fee Related US7405285B2 (en) | 2004-06-15 | 2005-09-22 | Immunostimulatory oligonucleotide multimers |
US11/876,913 Abandoned US20080193437A1 (en) | 2004-06-15 | 2007-10-23 | Immunostimulatory oligonucleotide multimers |
US12/565,151 Active 2026-06-03 US8420615B2 (en) | 2004-06-15 | 2009-09-23 | Immunostimulatory oligonucleotide multimers |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/153,054 Abandoned US20060014713A1 (en) | 2004-06-15 | 2005-06-15 | Immunostimulatory oligonucleotide multimers |
US11/234,396 Expired - Fee Related US7405285B2 (en) | 2004-06-15 | 2005-09-22 | Immunostimulatory oligonucleotide multimers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/565,151 Active 2026-06-03 US8420615B2 (en) | 2004-06-15 | 2009-09-23 | Immunostimulatory oligonucleotide multimers |
Country Status (20)
Country | Link |
---|---|
US (4) | US20060014713A1 (en) |
EP (2) | EP2901856B1 (en) |
JP (1) | JP4942646B2 (en) |
KR (1) | KR20070028537A (en) |
AU (1) | AU2005257938B2 (en) |
BR (1) | BRPI0512110A (en) |
CA (1) | CA2570786C (en) |
EE (1) | EE200700003A (en) |
ES (1) | ES2645158T3 (en) |
HK (1) | HK1211179A1 (en) |
HR (1) | HRP20070012A2 (en) |
HU (1) | HUE036894T2 (en) |
IL (1) | IL179973A0 (en) |
LV (1) | LV13641B (en) |
MA (1) | MA28976B1 (en) |
MX (1) | MXPA06014915A (en) |
NO (1) | NO20070263L (en) |
NZ (1) | NZ552522A (en) |
RU (1) | RU2007101039A (en) |
WO (1) | WO2006002038A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060142224A1 (en) * | 2000-09-26 | 2006-06-29 | Kandimalla Ekambar R | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US20060287262A1 (en) * | 2001-10-24 | 2006-12-21 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US20070105800A1 (en) * | 2005-11-07 | 2007-05-10 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US20090010938A1 (en) * | 2003-02-07 | 2009-01-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
US20090131347A1 (en) * | 1997-09-05 | 2009-05-21 | Eyal Raz | Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a th1 phenotype |
US8883174B2 (en) | 2009-03-25 | 2014-11-11 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
KR100917101B1 (en) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | Flexible metal laminate and production method thereof |
CN100334228C (en) * | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | Cimeric immunomodulatory compounds and methods of using the same |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
AR040996A1 (en) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US7851453B2 (en) * | 2003-01-16 | 2010-12-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US7569554B2 (en) * | 2003-05-16 | 2009-08-04 | Idera Pharmaceuticals, Inc. | Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents |
EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
AU2004259204B2 (en) * | 2003-07-15 | 2010-08-19 | Idera Pharmaceuticals, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
KR101107818B1 (en) | 2003-10-30 | 2012-01-31 | 콜레이 파마시티컬 그룹, 인코포레이티드 | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
AU2005326144A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
US7498425B2 (en) * | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
BRPI0512110A (en) * | 2004-06-15 | 2007-10-23 | Idera Pharmaceutical Inc | immunostimulatory oligonucleotide multimers |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
US20080009455A9 (en) * | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
SI2269622T1 (en) | 2005-07-01 | 2014-05-30 | Index Pharmaceuticals Ab | CpG oligonucleotides used for enhancing steroid activity in a steroid dependent patient |
PT2179737E (en) | 2005-07-01 | 2013-12-05 | Index Pharmaceuticals Ab | Modulating responsiveness to steroids |
CA2625969A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
JP5473336B2 (en) * | 2006-02-15 | 2014-04-16 | アディウタイド・ファーマスーティカルズ・ゲーエムベーハー | Compositions and methods relating to the formulation of oligonucleotides |
MX2009003398A (en) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
CN101878311A (en) * | 2007-08-01 | 2010-11-03 | 艾德拉药物股份有限公司 | Novel synthetic agonists of TLR9 |
GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
EP2943251B1 (en) * | 2013-01-08 | 2018-10-10 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
JPWO2015108047A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator |
WO2015108048A1 (en) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
EP3508198A1 (en) | 2014-06-04 | 2019-07-10 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
EP4029508A1 (en) * | 2014-10-10 | 2022-07-20 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonists and checkpoint inhibitors |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US10463686B2 (en) | 2016-09-15 | 2019-11-05 | Idera Pharmaceuticals, Inc. | Immune modulation with TLR9 agonists for cancer treatment |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
CA3174987A1 (en) * | 2020-03-09 | 2021-09-16 | Dynavax Technologies Corporation | Active booster immunization against tetanus, diphtheria and pertussis |
US20230061403A1 (en) * | 2020-03-09 | 2023-03-02 | Dynavax Technologies Corporation | Shingles vaccines comprising a tlr9 agonist |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5366878A (en) * | 1990-02-15 | 1994-11-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US5912332A (en) * | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
US6143881A (en) * | 1992-07-23 | 2000-11-07 | University Of Massachusetts Worcester | Hybrid oligonucleotide phosphorothioates |
US6346614B1 (en) * | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
US20040097719A1 (en) * | 2002-10-24 | 2004-05-20 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US20040156825A1 (en) * | 2003-02-07 | 2004-08-12 | Hybridon, Inc. | Short immunomodulatory oligonucleotides |
US20040266709A1 (en) * | 2000-09-26 | 2004-12-30 | Kandimalla Ekambar R | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US20050026861A1 (en) * | 2003-06-11 | 2005-02-03 | Kandimalla Ekambar R. | Stabilized immunomodulatory oligonucleotides |
US20060014713A1 (en) * | 2004-06-15 | 2006-01-19 | Hybridon, Inc. | Immunostimulatory oligonucleotide multimers |
US20060019918A1 (en) * | 2003-01-16 | 2006-01-26 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US20060094680A1 (en) * | 2004-06-15 | 2006-05-04 | Hybridon, Inc. | Immunostimulatory oligonucleotide multimers |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
CN1293192C (en) * | 2000-12-27 | 2007-01-03 | 戴纳瓦克斯技术公司 | Immunoregulation polynucleotide and using method thereof |
CN100334228C (en) | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | Cimeric immunomodulatory compounds and methods of using the same |
WO2003035836A2 (en) * | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
CA2508985A1 (en) * | 2002-12-23 | 2004-07-15 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
US20050004579A1 (en) | 2003-06-27 | 2005-01-06 | Schneider M. Bret | Computer-assisted manipulation of catheters and guide wires |
AU2004259204B2 (en) * | 2003-07-15 | 2010-08-19 | Idera Pharmaceuticals, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
-
2005
- 2005-06-15 BR BRPI0512110-8A patent/BRPI0512110A/en not_active IP Right Cessation
- 2005-06-15 KR KR1020077000993A patent/KR20070028537A/en not_active Application Discontinuation
- 2005-06-15 HU HUE15153954A patent/HUE036894T2/en unknown
- 2005-06-15 MX MXPA06014915A patent/MXPA06014915A/en active IP Right Grant
- 2005-06-15 WO PCT/US2005/020911 patent/WO2006002038A2/en active Application Filing
- 2005-06-15 CA CA2570786A patent/CA2570786C/en active Active
- 2005-06-15 RU RU2007101039/15A patent/RU2007101039A/en not_active Application Discontinuation
- 2005-06-15 NZ NZ552522A patent/NZ552522A/en unknown
- 2005-06-15 US US11/153,054 patent/US20060014713A1/en not_active Abandoned
- 2005-06-15 JP JP2007516632A patent/JP4942646B2/en active Active
- 2005-06-15 ES ES15153954.1T patent/ES2645158T3/en active Active
- 2005-06-15 AU AU2005257938A patent/AU2005257938B2/en not_active Ceased
- 2005-06-15 EP EP15153954.1A patent/EP2901856B1/en active Active
- 2005-06-15 EP EP05760552A patent/EP1765417A4/en not_active Withdrawn
- 2005-06-15 EE EEP200700003A patent/EE200700003A/en unknown
- 2005-09-22 US US11/234,396 patent/US7405285B2/en not_active Expired - Fee Related
-
2006
- 2006-12-11 IL IL179973A patent/IL179973A0/en unknown
- 2006-12-29 MA MA29600A patent/MA28976B1/en unknown
-
2007
- 2007-01-12 HR HR20070012A patent/HRP20070012A2/en not_active Application Discontinuation
- 2007-01-15 LV LVP-07-03A patent/LV13641B/en unknown
- 2007-01-15 NO NO20070263A patent/NO20070263L/en not_active Application Discontinuation
- 2007-10-23 US US11/876,913 patent/US20080193437A1/en not_active Abandoned
-
2009
- 2009-09-23 US US12/565,151 patent/US8420615B2/en active Active
-
2015
- 2015-12-09 HK HK15112153.1A patent/HK1211179A1/en not_active IP Right Cessation
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5366878A (en) * | 1990-02-15 | 1994-11-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5635377A (en) * | 1990-02-15 | 1997-06-03 | Worcester Foundation For Experimental Biology, Inc. | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5652355A (en) * | 1992-07-23 | 1997-07-29 | Worcester Foundation For Experimental Biology | Hybrid oligonucleotide phosphorothioates |
US6143881A (en) * | 1992-07-23 | 2000-11-07 | University Of Massachusetts Worcester | Hybrid oligonucleotide phosphorothioates |
US6346614B1 (en) * | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
US5912332A (en) * | 1996-07-26 | 1999-06-15 | Hybridon, Inc. | Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides |
US20040266709A1 (en) * | 2000-09-26 | 2004-12-30 | Kandimalla Ekambar R | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US20040266710A1 (en) * | 2000-09-26 | 2004-12-30 | Kandimalla Ekambar R. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US20060142224A1 (en) * | 2000-09-26 | 2006-06-29 | Kandimalla Ekambar R | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US20060019909A1 (en) * | 2001-10-24 | 2006-01-26 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US20040097719A1 (en) * | 2002-10-24 | 2004-05-20 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US20060019918A1 (en) * | 2003-01-16 | 2006-01-26 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US20040156825A1 (en) * | 2003-02-07 | 2004-08-12 | Hybridon, Inc. | Short immunomodulatory oligonucleotides |
US20050026861A1 (en) * | 2003-06-11 | 2005-02-03 | Kandimalla Ekambar R. | Stabilized immunomodulatory oligonucleotides |
US20060014713A1 (en) * | 2004-06-15 | 2006-01-19 | Hybridon, Inc. | Immunostimulatory oligonucleotide multimers |
US20060094680A1 (en) * | 2004-06-15 | 2006-05-04 | Hybridon, Inc. | Immunostimulatory oligonucleotide multimers |
US7498426B2 (en) * | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090131347A1 (en) * | 1997-09-05 | 2009-05-21 | Eyal Raz | Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a th1 phenotype |
US20060142224A1 (en) * | 2000-09-26 | 2006-06-29 | Kandimalla Ekambar R | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US7932367B2 (en) * | 2000-09-26 | 2011-04-26 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
US20080152662A1 (en) * | 2001-10-24 | 2008-06-26 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US7749975B2 (en) * | 2001-10-24 | 2010-07-06 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
US20060287262A1 (en) * | 2001-10-24 | 2006-12-21 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US7812000B2 (en) * | 2001-10-24 | 2010-10-12 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
US7517862B2 (en) * | 2001-10-24 | 2009-04-14 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
US20070173469A1 (en) * | 2001-10-24 | 2007-07-26 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
US20090010938A1 (en) * | 2003-02-07 | 2009-01-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
US7851454B2 (en) * | 2003-02-07 | 2010-12-14 | Idera Pharmaceutials, Inc. | Short immunomodulatory oligonucleotides |
US20100143328A1 (en) * | 2005-11-07 | 2010-06-10 | Sudhir Agrawal | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US20070105800A1 (en) * | 2005-11-07 | 2007-05-10 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US7470674B2 (en) * | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US8883174B2 (en) | 2009-03-25 | 2014-11-11 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US9186400B2 (en) | 2009-03-25 | 2015-11-17 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US9504742B2 (en) | 2009-03-25 | 2016-11-29 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US10722573B2 (en) | 2009-03-25 | 2020-07-28 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
Also Published As
Publication number | Publication date |
---|---|
WO2006002038A2 (en) | 2006-01-05 |
HK1211179A1 (en) | 2016-05-20 |
MA28976B1 (en) | 2007-11-01 |
JP4942646B2 (en) | 2012-05-30 |
HUE036894T2 (en) | 2018-08-28 |
KR20070028537A (en) | 2007-03-12 |
MXPA06014915A (en) | 2007-08-20 |
LV13641B (en) | 2008-07-20 |
WO2006002038A3 (en) | 2008-07-17 |
CA2570786A1 (en) | 2006-01-05 |
BRPI0512110A (en) | 2007-10-23 |
US8420615B2 (en) | 2013-04-16 |
US20100166736A1 (en) | 2010-07-01 |
HRP20070012A2 (en) | 2007-10-31 |
AU2005257938A1 (en) | 2006-01-05 |
US20070179103A1 (en) | 2007-08-02 |
IL179973A0 (en) | 2007-05-15 |
EP2901856A1 (en) | 2015-08-05 |
AU2005257938B2 (en) | 2010-11-11 |
US20060014713A1 (en) | 2006-01-19 |
NZ552522A (en) | 2009-04-30 |
NO20070263L (en) | 2007-03-09 |
EP1765417A4 (en) | 2009-03-25 |
ES2645158T3 (en) | 2017-12-04 |
EE200700003A (en) | 2007-06-15 |
EP2901856B1 (en) | 2017-08-09 |
EP1765417A2 (en) | 2007-03-28 |
RU2007101039A (en) | 2008-07-20 |
CA2570786C (en) | 2013-05-28 |
JP2008502688A (en) | 2008-01-31 |
US7405285B2 (en) | 2008-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8420615B2 (en) | Immunostimulatory oligonucleotide multimers | |
US7498425B2 (en) | Immunostimulatory oligonucleotide multimers | |
US7713535B2 (en) | Modulation of immunostimulatory properties by small oligonucleotide-based compounds | |
US8008267B2 (en) | Stabilized immunomodulatory oligonucleotides | |
US20040052763A1 (en) | Immunostimulatory RNA/DNA hybrid molecules | |
JP2009521218A (en) | Immunostimulatory action of palindromic immune modulatory oligonucleotides (IMO (TM)) containing palindromic segments of different lengths | |
US20070093439A1 (en) | Short immunomodulatory oligonucleotides | |
EP1725266A2 (en) | Potent mucosal immune response induced by modified immunomodulatory oligonucleotides | |
CN101426370A (en) | Immunostimulatory oligonucleotide multimers | |
MXPA06006506A (en) | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IDERA PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AGRAWAL, SUDHIR;KANDIMALLA, EKAMBAR R.;YU, DONG;REEL/FRAME:020286/0910 Effective date: 20071127 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |